@NP	Conditioned medium of olfactory ensheathing cells	1
@NP	Conditioned medium	1
@NP	olfactory ensheathing cells	23
@NP	the functional recovery and axonal regeneration	60
@NP	contusive spinal cord injury A B S T R A C T Objective	114
@NP	the effectiveness	186
@NP	the potential role	208
@NP	olfactory ensheathing cell conditioned medium -LRB- OEC-M -RRB-	230
@NP	olfactory ensheathing cell conditioned medium	230
@NP	olfactory ensheathing cell	230
@NP	OEC-M	277
@NP	contusive spinal cord injury -LRB- SCI -RRB-	293
@NP	contusive spinal cord injury	293
@NP	SCI	323
@NP	Methods	329
@NP	The contusive SCI model	338
@NP	NYU weight-drop impactor	381
@NP	T10 segment	409
@NP	Male Sprague-Dawley rats	422
@NP	intraperitoneal injection	456
@NP	control medium -LRB- Con-M , n = 18 -RRB-	485
@NP	control medium	485
@NP	Con-M , n = 18	501
@NP	Con-M	501
@NP	n = 18	508
@NP	n	508
@NP	18	510
@NP	low dose OEC-M -LRB- n = 18 -RRB-	515
@NP	low dose OEC-M	515
@NP	n	531
@NP	18	533
@NP	high dose OEC-M -LRB- n = 18 -RRB-	541
@NP	high dose OEC-M	541
@NP	n	558
@NP	18	560
@NP	Immunofluorescence	565
@NP	the purity of cultured OECs	610
@NP	the purity	610
@NP	OECs	633
@NP	BBB score	639
@NP	the functional recovery	668
@NP	BDNF concentrations of OEC-M , Con-M and rats plasma samples	693
@NP	BDNF concentrations	693
@NP	OEC-M , Con-M and rats plasma samples	716
@NP	ELISA	772
@NP	Conventional MRI and diffusion tensor tractography -LRB- DTT -RRB-	779
@NP	Conventional MRI and diffusion tensor tractography	779
@NP	Conventional MRI	779
@NP	diffusion tensor tractography	800
@NP	DTT	831
@NP	the repair process of SCI	862
@NP	the repair process	862
@NP	SCI	884
@NP	Diffusion tensor imaging -LRB- DTI -RRB- and immunohistochemistry of NF200	889
@NP	Diffusion tensor imaging -LRB- DTI -RRB-	889
@NP	Diffusion tensor imaging	889
@NP	DTI	915
@NP	immunohistochemistry of NF200	924
@NP	immunohistochemistry	924
@NP	NF200	948
@NP	the axonal regeneration	983
@NP	Results	1008
@NP	the systemic delivery of treatment	1023
@NP	the systemic delivery	1023
@NP	treatment	1048
@NP	BBB scores and BDNF levels in peripheral blood	1059
@NP	BBB scores	1059
@NP	BDNF levels in peripheral blood	1074
@NP	BDNF levels	1074
@NP	peripheral blood	1089
@NP	OEC-M	1135
@NP	treated groups	1141
@NP	Con-M group	1164
@NP	MRI and DTT	1177
@NP	MRI	1177
@NP	DTT	1185
@NP	a better radiological recovery	1202
@NP	SCI	1239
@NP	OEC-M treated groups	1246
@NP	higher dose of OEC-M	1271
@NP	higher dose	1271
@NP	OEC-M	1286
@NP	better outcomes	1314
@NP	DTI and NF200 staining	1331
@NP	the OEC-M treatment	1363
@NP	axonal regeneration	1392
@NP	the injury epicenter	1419
@NP	no axonal regeneration	1444
@NP	the lesion site	1483
@NP	Conclusion	1500
@NP	The results	1512
@NP	the OEC-M treatment	1538
@NP	the functional recovery	1567
@NP	the axonal regeneration around the injury epicenter	1604
@NP	the axonal regeneration	1604
@NP	the injury epicenter	1635
@NP	contusive SCI	1662
@NP	This strategy	1677
@NP	a novel cell-free OEC based therapy to effectively treat SCI	1702
@NP	a novel cell-free OEC	1702
@NP	therapy	1730
@NP	SCI	1759
@NP	Introduction Spinal cord injury -LRB- SCI -RRB-	1768
@NP	Introduction Spinal cord injury	1768
@NP	Introduction	1768
@NP	Spinal cord injury	1781
@NP	SCI	1801
@NP	a devastating form	1809
@NP	trauma resulting in the permanent loss of motor , sensory and autonomic function	1831
@NP	trauma	1831
@NP	the permanent loss of motor , sensory and autonomic function	1851
@NP	the permanent loss	1851
@NP	motor , sensory and autonomic function	1873
@NP	motor	1873
@NP	sensory	1880
@NP	autonomic function	1892
@NP	the poor self-repair capability of central nerve system -LRB- CNS -RRB-	1919
@NP	the poor self-repair capability	1919
@NP	central nerve system -LRB- CNS -RRB-	1954
@NP	central nerve system	1954
@NP	CNS	1975
@NP	spinal cord injury	1981
@NP	a therapeutic challenge to date	2009
@NP	a therapeutic challenge	2009
@NP	date	2036
@NP	the last two decades	2047
@NP	a potential effective therapy for spinal cord injury	2072
@NP	a potential effective therapy	2072
@NP	spinal cord injury	2106
@NP	surgical transplantation	2126
@NP	a series	2154
@NP	cell types	2166
@NP	olfactory ensheathing cells	2188
@NP	OECs	2217
@NP	Schwann cells	2224
@NP	fate-restricted neural and glial precursors	2239
@NP	undifferentiated neural stem cells	2284
@NP	bone marrow stromal cells	2324
@NP	Tetzlaff et al. , 2011	2390
@NP	Tetzlaff	2390
@NP	et al.	2399
@NP	2011	2407
@NP	OECs , derived from the nerve fiber layer of olfactory bulb and nasal mucosa ,	2414
@NP	OECs	2414
@NP	the nerve fiber layer of olfactory bulb and nasal mucosa	2433
@NP	the nerve fiber layer	2433
@NP	olfactory bulb and nasal mucosa	2458
@NP	olfactory bulb	2458
@NP	nasal mucosa	2477
@NP	the regeneration of primary olfactory system	2514
@NP	the regeneration	2514
@NP	primary olfactory system	2534
@NP	a lesion -LRB- Franssen et al. , 2007 -RRB-	2565
@NP	a lesion	2565
@NP	Franssen	2575
@NP	et al. , 2007	2584
@NP	et al.	2584
@NP	2007	2592
@NP	the new axons	2624
@NP	olfactory epithelium	2653
@NP	the olfactory bulb -LRB- Raisman , 1985 -RRB-	2677
@NP	the olfactory bulb	2677
@NP	Raisman , 1985	2697
@NP	Raisman	2697
@NP	1985	2706
@NP	this axon growth promoting property	2724
@NP	this axon growth	2724
@NP	property	2751
@NP	OECs	2761
@NP	a promising candidate for the cell-based treatment of SCI	2799
@NP	a promising candidate	2799
@NP	the cell-based treatment of SCI	2825
@NP	the cell-based treatment	2825
@NP	SCI	2853
@NP	Earlier studies	2858
@NP	transplantation of OECs into spinal cord lesions	2897
@NP	transplantation	2897
@NP	OECs into spinal cord lesions	2916
@NP	OECs	2916
@NP	spinal cord lesions	2926
@NP	neural regeneration	2958
@NP	locomotor function	2987
@NP	progressive tissue loss	3015
@NP	axonal remyelination	3053
@NP	Li	3075
@NP	et al. , 1998	3078
@NP	et al.	3078
@NP	1998	3086
@NP	Lopez-Vales et al. , 2006	3092
@NP	Lopez-Vales	3092
@NP	et al. , 2006	3104
@NP	et al.	3104
@NP	2006	3112
@NP	Lu et al. , 2002	3118
@NP	Lu	3118
@NP	et al. , 2002	3121
@NP	et al.	3121
@NP	2002	3129
@NP	Pearse et al. , 2007	3135
@NP	Pearse	3135
@NP	et al. , 2007	3142
@NP	et al.	3142
@NP	2007	3150
@NP	Plant et al. , 2003	3156
@NP	Plant	3156
@NP	et al. , 2003	3162
@NP	et al.	3162
@NP	2003	3170
@NP	Ramer et al. , 2004	3176
@NP	Ramer	3176
@NP	et al. , 2004	3182
@NP	et al.	3182
@NP	2004	3190
@NP	Sasaki et al. , 2004	3196
@NP	Sasaki	3196
@NP	et al. , 2004	3203
@NP	et al.	3203
@NP	2004	3211
@NP	Ziegler et al. , 2011	3217
@NP	Ziegler	3217
@NP	et al. , 2011	3225
@NP	et al.	3225
@NP	2011	3233
@NP	the therapeutic effects of OECs	4303
@NP	the therapeutic effects	4303
@NP	OECs	4330
@NP	other studies	4362
@NP	behavioral improvements and spinal cord repair	4394
@NP	behavioral improvements	4394
@NP	spinal cord repair	4422
@NP	OECs transplantation	4447
@NP	Aoki	4469
@NP	et al. , 2010	4474
@NP	et al.	4474
@NP	2010	4482
@NP	Barakat et al. , 2005	4488
@NP	Barakat	4488
@NP	et al. , 2005	4496
@NP	et al.	4496
@NP	2005	4504
@NP	Bretzner et al. , 2010	4510
@NP	Bretzner	4510
@NP	et al. , 2010	4519
@NP	et al.	4519
@NP	2010	4527
@NP	Lu et al. , 2006	4533
@NP	Lu	4533
@NP	et al. , 2006	4536
@NP	et al.	4536
@NP	2006	4544
@NP	Pearse et al. , 2007	4550
@NP	Pearse	4550
@NP	et al. , 2007	4557
@NP	et al.	4557
@NP	2007	4565
@NP	Takami et al. , 2002	4571
@NP	Takami	4571
@NP	et al. , 2002	4578
@NP	et al.	4578
@NP	2002	4586
@NP	the hostile environment and adaptive immune response in the injured spinal cord	5073
@NP	the hostile environment	5073
@NP	adaptive immune response in the injured spinal cord	5101
@NP	adaptive immune response	5101
@NP	the injured spinal cord	5129
@NP	the survival rates of transplanted OECs are reported to be low	5154
@NP	the survival	5154
@NP	rates of transplanted OECs	5167
@NP	rates	5167
@NP	transplanted OECs	5176
@NP	varying	5218
@NP	approximately 0.3 % to 3 %	5231
@NP	Barakat	5257
@NP	et al. , 2005	5265
@NP	et al.	5265
@NP	2005	5273
@NP	Pearse et al. , 2007	5279
@NP	Pearse	5279
@NP	et al. , 2007	5286
@NP	et al.	5286
@NP	2007	5294
@NP	Roet et al. , 2012	5300
@NP	Roet	5300
@NP	et al. , 2012	5305
@NP	et al.	5305
@NP	2012	5313
@NP	Torres - Espin et al. , 2014	5319
@NP	Torres	5319
@NP	Espin et al. , 2014	5327
@NP	Espin	5327
@NP	et al. , 2014	5333
@NP	et al.	5333
@NP	2014	5341
@NP	only a small number of transplanted OECs	5364
@NP	only a small number	5364
@NP	transplanted OECs	5387
@NP	beneficial effects	5411
@NP	a relatively short period post injury	5437
@NP	All these evidences	5476
@NP	the properties of OECs and the pathology of spinal cord injury	5512
@NP	the properties of OECs	5512
@NP	the properties	5512
@NP	OECs	5530
@NP	the pathology of spinal cord injury	5539
@NP	the pathology	5539
@NP	spinal cord injury	5556
@NP	us	5583
@NP	a novel OECs based therapy for SCI	5601
@NP	a novel OECs	5601
@NP	therapy for SCI	5620
@NP	therapy	5620
@NP	SCI	5632
@NP	Olfactory ensheathing cell conditioned medium	5637
@NP	Olfactory ensheathing cell	5637
@NP	OEC-M	5683
@NP	various neurotrophic factors that can promote neural regeneration	5699
@NP	various neurotrophic factors	5699
@NP	neural regeneration	5745
@NP	the repair	5777
@NP	injured spinal cord	5791
@NP	Lopez-Vales	5812
@NP	et al.	5824
@NP	2004b , 2006 ; Richter and Roskanis , 2008 ; Torres - Espin et al.	5832
@NP	2004b , 2006	5832
@NP	2004b	5832
@NP	2006	5839
@NP	Richter and Roskanis , 2008	5845
@NP	Richter and Roskanis	5845
@NP	2008	5867
@NP	Torres - Espin et al.	5873
@NP	Torres	5873
@NP	Espin et al.	5881
@NP	Espin	5881
@NP	et al.	5887
@NP	2013	5895
@NP	the systemic delivery of OEC-M	5912
@NP	the systemic delivery	5912
@NP	OEC-M	5937
@NP	the low survival rate	5955
@NP	grafted cells	5980
@NP	the immune rejection	5995
@NP	the surgery needed for the cell transplantation	6017
@NP	the surgery	6017
@NP	the cell transplantation	6040
@NP	other limitations of cell transplantation	6069
@NP	other limitations	6069
@NP	cell transplantation	6090
@NP	the present study	6118
@NP	the consistent intraperitoneally administration of OEC-M	6172
@NP	the consistent intraperitoneally administration	6172
@NP	OEC-M	6223
@NP	functional recovery and axonal regeneration	6246
@NP	functional recovery	6246
@NP	axonal regeneration	6270
@NP	a contusive SCI	6296
@NP	The results	6313
@NP	a new cell-free OECs based therapy for spinal cord injury	6337
@NP	a new cell-free OECs	6337
@NP	therapy for spinal cord injury	6364
@NP	therapy	6364
@NP	spinal cord injury	6376
@NP	Results Fig. 1 .	6400
@NP	Results	6400
@NP	Fig. 1	6409
@NP	OECs	6417
@NP	culture with the nuclear staining -LRB- DAPI -RRB- and immunostained for P75NTR	6425
@NP	the nuclear staining -LRB- DAPI -RRB-	6438
@NP	the nuclear staining	6438
@NP	DAPI	6460
@NP	× 200	6496
@NP	The	6503
@NP	image	6513
@NP	> 90 % of cells were P75	6529
@NP	>	6529
@NP	90 % of cells	6531
@NP	90 %	6531
@NP	cells	6538
@NP	P75	6549
@NP	+	6552
@NP	Scale bar	6555
@NP	50 μm	6568
@NP	Fig. 2 .	6576
@NP	Fig.	6576
@NP	2	6581
@NP	Locomotion test	6584
@NP	The BBB open field locomotion score	6609
@NP	every three days	6659
@NP	the injury	6682
@NP	The number of rats -LRB- n -RRB- for each group at each time point	6694
@NP	The number	6694
@NP	rats -LRB- n -RRB- for each group at each time point	6708
@NP	rats -LRB- n -RRB-	6708
@NP	rats	6708
@NP	n	6714
@NP	each group at each time point	6721
@NP	each group	6721
@NP	each time point	6735
@NP	6	6754
@NP	Data	6757
@NP	mean ± SD	6781
@NP	The result	6792
@NP	significant differences	6813
@NP	the three groups	6843
@NP	surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	6866
@NP	surgery	6866
@NP	two-way ANOVA , p < 0.05	6875
@NP	two-way ANOVA , p <	6875
@NP	two-way ANOVA	6875
@NP	p <	6890
@NP	p	6890
@NP	<	6892
@NP	0.05	6894
@NP	LSD-t-test	6901
@NP	two groups at each time point	6934
@NP	two groups	6934
@NP	each time point	6948
@NP	ap	6965
@NP	< 0.05 high dose	6968
@NP	<	6968
@NP	0.05 high dose	6970
@NP	OEC-M group vs. time-matched low dose OEC-M group ; bp < 0.05 high dose	6985
@NP	OEC-M group vs. time-matched low dose OEC-M group	6985
@NP	OEC-M group	6985
@NP	time-matched low dose OEC-M group	7001
@NP	bp < 0.05 high dose	7036
@NP	bp <	7036
@NP	bp	7036
@NP	0.05 high dose	7041
@NP	OEC-M group vs Con-M ; cp <	7056
@NP	OEC-M group vs Con-M	7056
@NP	OEC-M group	7056
@NP	Con-M	7071
@NP	cp <	7078
@NP	cp	7078
@NP	<	7081
@NP	0.05 Con-M vs low dose OEC-M group	7083
@NP	0.05 Con-M	7083
@NP	low dose OEC-M group	7097
@NP	Fig. 3 .	7120
@NP	Fig.	7120
@NP	3	7125
@NP	The concentration of BDNF in peripheral blood .	7128
@NP	The concentration	7128
@NP	BDNF	7149
@NP	peripheral blood	7157
@NP	ELISA	7175
@NP	the BDNF levels of test samples	7200
@NP	the BDNF levels	7200
@NP	test samples	7219
@NP	Con-M group -LRB- n = 6 -RRB-	7237
@NP	Con-M group	7237
@NP	n	7250
@NP	6	7252
@NP	low dose OEC-M group -LRB- n = 6 -RRB-	7256
@NP	low dose OEC-M group	7256
@NP	n	7278
@NP	6	7280
@NP	high dose OEC-M group -LRB- n = 6 -RRB-	7287
@NP	high dose OEC-M group	7287
@NP	n	7310
@NP	6	7312
@NP	week 1 , week 3 and week 6	7318
@NP	week 1	7318
@NP	week 3	7326
@NP	week 6	7337
@NP	Results	7358
@NP	mean ± SD	7383
@NP	-LRB- A -RRB- Comparisons	7394
@NP	two groups at a certain time point	7433
@NP	two groups	7433
@NP	a certain time point	7447
@NP	-LRB- B -RRB- BDNF levels	7469
@NP	-LRB- B -RRB-	7469
@NP	BDNF levels	7473
@NP	two time points in a certain group	7507
@NP	two time points	7507
@NP	a certain group	7526
@NP	ap	7543
@NP	< 0.05 high dose	7546
@NP	<	7546
@NP	0.05 high dose	7548
@NP	OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	7563
@NP	OEC-M group vs. low dose OEC-M group	7563
@NP	OEC-M group	7563
@NP	low dose OEC-M group	7579
@NP	bp < 0.05 high dose	7601
@NP	bp <	7601
@NP	bp	7601
@NP	0.05 high dose	7606
@NP	OEC-M group vs Con-M ; cp <	7621
@NP	OEC-M group vs Con-M	7621
@NP	OEC-M group	7621
@NP	Con-M	7636
@NP	cp <	7643
@NP	cp	7643
@NP	<	7646
@NP	0.05 Con-M vs low dose OEC-M group	7648
@NP	0.05 Con-M	7648
@NP	low dose OEC-M group	7662
@NP	Fig. 4 .	7685
@NP	Fig.	7685
@NP	4	7690
@NP	The Fractional anisotropy -LRB- FA -RRB- value of the lesion segment .	7693
@NP	The Fractional anisotropy -LRB- FA -RRB-	7693
@NP	The Fractional anisotropy	7693
@NP	FA	7720
@NP	value of the lesion segment	7724
@NP	value	7724
@NP	the lesion segment	7733
@NP	Diffusion tensor imaging scan	7753
@NP	Diffusion tensor	7753
@NP	imaging	7770
@NP	the FA value of the rats -LRB- n = 6 -RRB-	7809
@NP	the FA value	7809
@NP	the rats -LRB- n = 6 -RRB-	7825
@NP	the rats	7825
@NP	n	7835
@NP	6	7837
@NP	each group every week	7845
@NP	each group	7845
@NP	every week	7856
@NP	the contusive spinal cord injury	7873
@NP	Results	7907
@NP	mean ± SD	7932
@NP	FA values	7943
@NP	SCI	7979
@NP	there	7987
@NP	differences	8012
@NP	the three groups after surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	8030
@NP	the three groups	8030
@NP	surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	8053
@NP	surgery	8053
@NP	two-way ANOVA , p < 0.05	8062
@NP	two-way ANOVA , p <	8062
@NP	two-way ANOVA	8062
@NP	p <	8077
@NP	p	8077
@NP	<	8079
@NP	0.05	8081
@NP	LSD-t-test	8088
@NP	two groups at each time point	8121
@NP	two groups	8121
@NP	each time point	8135
@NP	ap	8152
@NP	< 0.05 high dose	8155
@NP	<	8155
@NP	0.05 high dose	8157
@NP	OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	8172
@NP	OEC-M group vs. low dose OEC-M group	8172
@NP	OEC-M group	8172
@NP	low dose OEC-M group	8188
@NP	bp < 0.05 high dose	8210
@NP	bp <	8210
@NP	bp	8210
@NP	0.05 high dose	8215
@NP	OEC-M group vs Con-M ; cp <	8230
@NP	OEC-M group vs Con-M	8230
@NP	OEC-M group	8230
@NP	Con-M	8245
@NP	cp <	8252
@NP	cp	8252
@NP	<	8255
@NP	0.05 Con-M vs low dose OEC-M group	8257
@NP	0.05 Con-M	8257
@NP	low dose OEC-M group	8271
@NP	Fig. 5 .	8294
@NP	Fig.	8294
@NP	5	8299
@NP	T1-weighted images -LRB- T1WI -RRB- of the spinal cord after injury .	8302
@NP	T1-weighted images	8302
@NP	T1WI	8322
@NP	the spinal cord after injury	8331
@NP	the spinal cord	8331
@NP	injury	8353
@NP	T1WI	8361
@NP	less noticeable changes	8376
@NP	SCI	8406
@NP	The arrow	8411
@NP	the injury site	8431
@NP	Fig. 6 .	8449
@NP	Fig.	8449
@NP	6	8454
@NP	T2-weighted images -LRB- T2WI -RRB- of the spinal cord after injury .	8457
@NP	T2-weighted images	8457
@NP	T2WI	8477
@NP	the spinal cord after injury	8486
@NP	the spinal cord	8486
@NP	injury	8508
@NP	T2WI	8516
@NP	a hypointense region	8530
@NP	the spinal cord parenchyma	8558
@NP	a hperintense region	8600
@NP	the contusive injury site	8624
@NP	The arrow	8651
@NP	the injury site	8671
@NP	Fig. 7 .	8689
@NP	Fig.	8689
@NP	7	8694
@NP	Diffusion tensor tractography -LRB- DTT -RRB- of SCI .	8697
@NP	Diffusion tensor tractography	8697
@NP	DTT	8728
@NP	SCI	8736
@NP	DTT	8741
@NP	the depression of the injured spinal cord	8752
@NP	the depression	8752
@NP	the injured spinal cord	8770
@NP	the interruption of the fiber tracks	8798
@NP	the interruption	8798
@NP	the fiber tracks	8818
@NP	Fig. 8 .	8837
@NP	Fig.	8837
@NP	8	8842
@NP	Hematoxylin and eosin -LRB- HE -RRB- staining of lesion site .	8845
@NP	Hematoxylin and eosin -LRB- HE -RRB-	8845
@NP	Hematoxylin and eosin	8845
@NP	HE	8868
@NP	staining of lesion site	8872
@NP	staining	8872
@NP	lesion site	8884
@NP	All cell nucleuses	8897
@NP	Cytoplasm	8942
@NP	pink	8964
@NP	Scale bar	8970
@NP	200 μm	8983
@NP	Fig. 9 .	8992
@NP	Fig.	8992
@NP	9	8997
@NP	Immunohistochemistry staining of NF200 in the injury epicenter .	9000
@NP	Immunohistochemistry staining	9000
@NP	NF200	9033
@NP	the injury epicenter	9042
@NP	Positive axons and neuron	9064
@NP	Positive axons	9064
@NP	neuron	9083
@NP	brown	9103
@NP	All cell nucleuses	9110
@NP	Scale bar	9148
@NP	100 μm	9161
@NP	Fig. 10 .	9170
@NP	Fig.	9170
@NP	10	9175
@NP	Immunohistochemistry staining	9179
@NP	NF200	9212
@NP	the region around the injury epicenter	9221
@NP	the region	9221
@NP	the injury epicenter	9239
@NP	Positive axons and neuron	9261
@NP	Positive axons	9261
@NP	neuron	9280
@NP	brown	9300
@NP	All cell nucleuses	9307
@NP	Scale bar	9345
@NP	100 μm	9358
@NP	Fig. 11 .	9367
@NP	Fig.	9367
@NP	11	9372
@NP	The NF200 positive density in the gray matter .	9376
@NP	The NF200	9376
@NP	positive density in the gray matter	9386
@NP	positive density	9386
@NP	the gray matter	9406
@NP	NF200 positive density	9423
@NP	the gray matter	9449
@NP	the sections	9468
@NP	Con-M group -LRB- n = 5 -RRB-	9486
@NP	Con-M group	9486
@NP	n	9499
@NP	5	9501
@NP	low dose OEC-M group -LRB- n = 5 -RRB-	9505
@NP	low dose OEC-M group	9505
@NP	n	9527
@NP	5	9529
@NP	high dose OEC-M group -LRB- n = 5 -RRB-	9536
@NP	high dose OEC-M group	9536
@NP	n	9559
@NP	5	9561
@NP	week 1 , week 3 and week 6	9567
@NP	week 1	9567
@NP	week 3	9575
@NP	week 6	9586
@NP	Image	9612
@NP	Pro Plus 6	9618
@NP	Pro	9618
@NP	6	9627
@NP	Data	9630
@NP	mean ± SD	9652
@NP	-LRB- A -RRB- The NF200 positive density in the gray area	9663
@NP	-LRB- A -RRB-	9663
@NP	The NF200	9667
@NP	positive density in the gray area	9677
@NP	positive density	9677
@NP	the gray area	9697
@NP	two groups at week 1 , week 3 and week 6 post surgery	9732
@NP	two groups	9732
@NP	week 1 , week 3 and week 6 post surgery	9746
@NP	week 1	9746
@NP	week 3	9754
@NP	week 6 post surgery	9765
@NP	-LRB- B -RRB- LSD-t-test	9786
@NP	-LRB- B -RRB-	9786
@NP	LSD-t-test	9790
@NP	two time points in each group	9823
@NP	two time points	9823
@NP	each group	9842
@NP	ap	9854
@NP	< 0.05 high dose	9857
@NP	<	9857
@NP	0.05 high dose	9859
@NP	OEC-M group vs. low dose OEC-M group ; bp < 0.05 high dose	9874
@NP	OEC-M group vs. low dose OEC-M group	9874
@NP	OEC-M group	9874
@NP	low dose OEC-M group	9890
@NP	bp < 0.05 high dose	9912
@NP	bp <	9912
@NP	bp	9912
@NP	0.05 high dose	9917
@NP	OEC-M group vs Con-M ; cp <	9932
@NP	OEC-M group vs Con-M	9932
@NP	OEC-M group	9932
@NP	Con-M	9947
@NP	cp <	9954
@NP	cp	9954
@NP	<	9957
@NP	0.05 Con-M vs low dose OEC-M group	9959
@NP	0.05 Con-M	9959
@NP	low dose OEC-M group	9973
@NP	2.1	9996
@NP	Characterization of olfactory ensheathing cells	10001
@NP	Characterization	10001
@NP	olfactory ensheathing cells	10021
@NP	immunofluorescence	10052
@NP	200 × magnification	10077
@NP	different fields -LRB- n = 5 -RRB-	10097
@NP	different fields	10097
@NP	n	10115
@NP	5	10117
@NP	the fluorescence microscopy	10147
@NP	the purity of OECs	10188
@NP	the purity	10188
@NP	OECs	10202
@NP	the number of DAPI-labeled nuclei	10220
@NP	the number	10220
@NP	DAPI-labeled nuclei	10234
@NP	the number	10259
@NP	P75NTR immunoreactive cells	10273
@NP	rabbit	10302
@NP	anti-rat P75NTR monoclonal antibody , 1:50 Proteintech , Chicago , IL , USA	10309
@NP	anti-rat P75NTR monoclonal antibody	10309
@NP	1:50 Proteintech , Chicago	10346
@NP	IL	10373
@NP	USA	10377
@NP	Our data	10383
@NP	93 ± 3.54 % of cells	10406
@NP	93 ± 3.54 %	10406
@NP	93	10406
@NP	cells	10420
@NP	P75NTR positive -LRB- Fig. 1 -RRB-	10431
@NP	P75NTR	10431
@NP	Fig. 1	10448
@NP	2.2	10457
@NP	Functional recovery evaluated by BBB	10462
@NP	Functional recovery	10462
@NP	BBB	10495
@NP	The BBB open field score	10505
@NP	the locomotor recovery	10551
@NP	SCI	10580
@NP	All the rats	10585
@NP	the surgery	10619
@NP	different degrees of recovery -LRB- Fig. 2 -RRB-	10645
@NP	different degrees	10645
@NP	recovery -LRB- Fig. 2 -RRB-	10666
@NP	recovery	10666
@NP	Fig. 2	10676
@NP	There	10685
@NP	significant differences	10696
@NP	the Con-M group , the low dose OEC-M group and the high dose OEC-M group	10726
@NP	the Con-M group	10726
@NP	the low dose OEC-M group	10743
@NP	the high dose OEC-M group	10772
@NP	the 6 weeks	10805
@NP	the surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	10823
@NP	the surgery	10823
@NP	two-way ANOVA , p < 0.05	10836
@NP	two-way ANOVA , p <	10836
@NP	two-way ANOVA	10836
@NP	p <	10851
@NP	p	10851
@NP	<	10853
@NP	0.05	10855
@NP	the early phase	10869
@NP	there	10886
@NP	no significant differences between groups	10897
@NP	no significant differences	10897
@NP	groups	10932
@NP	9 days to 42 days after surgery	10952
@NP	9 days	10952
@NP	42 days after surgery	10962
@NP	42 days	10962
@NP	surgery	10976
@NP	the Con-M group , BBB scores of the low dose	10998
@NP	the Con-M group	10998
@NP	BBB scores of the low dose	11015
@NP	BBB scores	11015
@NP	the low dose	11029
@NP	OEC-M group and high dose OEC-M group	11042
@NP	OEC-M group	11042
@NP	high dose OEC-M group	11058
@NP	significantly higher respectively -LRB- p < 0.05 -RRB-	11085
@NP	significantly higher respectively	11085
@NP	p < 0.05	11120
@NP	p	11120
@NP	< 0.05	11122
@NP	<	11122
@NP	0.05	11124
@NP	there	11135
@NP	a significant difference	11150
@NP	high dose OEC-M group and low dose OEC-M	11183
@NP	day 12 to day 30 after the surgery -LRB- p < 0.05 -RRB-	11227
@NP	day 12	11227
@NP	day 30 after the surgery -LRB- p < 0.05 -RRB-	11237
@NP	day 30	11237
@NP	the surgery -LRB- p < 0.05 -RRB-	11250
@NP	the surgery	11250
@NP	p < 0.05	11263
@NP	p	11263
@NP	< 0.05	11264
@NP	<	11264
@NP	0.05	11265
@NP	2.3	11272
@NP	Concentration	11277
@NP	brain	11294
@NP	neurotrophic factor -LRB- BDNF -RRB-	11308
@NP	neurotrophic factor	11308
@NP	BDNF	11329
@NP	peripheral blood	11338
@NP	ELISA BDNF concentrations of the Con-M , OEC-M and peripheral blood	11369
@NP	ELISA BDNF concentrations	11369
@NP	the Con-M , OEC-M and peripheral blood	11398
@NP	the Con-M	11398
@NP	OEC-M	11409
@NP	peripheral blood	11419
@NP	ELISA -LRB- BNDF ELISA kit , CUSABIO , Wuhan , China -RRB-	11455
@NP	ELISA	11455
@NP	BNDF ELISA kit , CUSABIO , Wuhan , China	11462
@NP	BNDF ELISA kit	11462
@NP	CUSABIO	11478
@NP	Wuhan	11487
@NP	China	11494
@NP	The values of BDNF in the test samples	11502
@NP	The values	11502
@NP	BDNF in the test samples	11516
@NP	BDNF	11516
@NP	the test samples	11524
@NP	the standard curve	11566
@NP	It	11586
@NP	OEC-M and Con-M	11603
@NP	183.64 ± 12.61 pg/ml and 39.12 ± 14.21 pg/ml BDNF	11629
@NP	183.64 ± 12.61 pg/ml	11629
@NP	183.64 ±	11629
@NP	12.61 pg/ml	11638
@NP	39.12 ± 14.21 pg/ml BDNF	11654
@NP	39.12 ±	11654
@NP	14.21 pg/ml BDNF	11662
@NP	the systemic delivery of the treatment	11699
@NP	the systemic delivery	11699
@NP	the treatment	11724
@NP	BDNF in peripheral blood	11739
@NP	BDNF	11739
@NP	peripheral blood	11747
@NP	Fig. 3	11785
@NP	a major secretion of OEC	11797
@NP	a major secretion	11797
@NP	OEC	11818
@NP	the increased concentration of BDNF in the peripheral blood	11823
@NP	the increased concentration	11823
@NP	BDNF in the peripheral blood	11854
@NP	BDNF	11854
@NP	the peripheral blood	11862
@NP	the OEC secretome	11898
@NP	the blood	11951
@NP	the rat	11974
@NP	BDNF level	11983
@NP	significantly higher in the OEC-M treated groups	11998
@NP	the OEC-M	12022
@NP	high dose and low dose OEC-M group	12048
@NP	high dose	12048
@NP	low dose OEC-M group	12062
@NP	the time-matched Con-M group at all three time points -LRB- p < 0.05 -RRB-	12096
@NP	the time-matched Con-M group	12096
@NP	all three time points -LRB- p < 0.05 -RRB-	12128
@NP	all three time points	12128
@NP	p < 0.05	12151
@NP	p	12151
@NP	< 0.05	12153
@NP	<	12153
@NP	0.05	12155
@NP	week 1	12165
@NP	BDNF level in high dose OEC-M group	12173
@NP	BDNF level	12173
@NP	high dose OEC-M group	12187
@NP	low dose group -LRB- p > 0.05 -RRB-	12234
@NP	low dose group	12234
@NP	p > 0.05	12250
@NP	p	12250
@NP	> 0.05	12252
@NP	>	12252
@NP	0.05	12254
@NP	significant differences	12270
@NP	these two groups	12310
@NP	week 3 and week 6	12330
@NP	week 3	12330
@NP	week 6	12341
@NP	injury -LRB- p < 0.05 -RRB- -LRB- Fig. 3A -RRB-	12354
@NP	injury -LRB- p < 0.05 -RRB-	12354
@NP	injury	12354
@NP	p < 0.05	12362
@NP	p	12362
@NP	< 0.05	12364
@NP	<	12364
@NP	0.05	12366
@NP	Fig. 3A	12373
@NP	There	12383
@NP	no significant differences	12394
@NP	Con-M group between any time points -LRB- p > 0.05 -RRB-	12424
@NP	Con-M group	12424
@NP	any time points -LRB- p > 0.05 -RRB-	12444
@NP	any time points	12444
@NP	p > 0.05	12461
@NP	p	12461
@NP	> 0.05	12463
@NP	>	12463
@NP	0.05	12465
@NP	the low dose OEC-M group and high dose OEC-M group	12486
@NP	the low dose OEC-M group	12486
@NP	high dose OEC-M group	12515
@NP	BDNF concentration in peripheral blood	12538
@NP	BDNF concentration	12538
@NP	peripheral blood	12560
@NP	week 1	12606
@NP	week 3	12616
@NP	the differences	12627
@NP	week 6 -LRB- p < 0.05 -RRB- -LRB- Fig. 3B -RRB-	12667
@NP	week 6 -LRB- p < 0.05 -RRB-	12667
@NP	week 6	12667
@NP	p < 0.05	12675
@NP	p	12675
@NP	< 0.05	12677
@NP	<	12677
@NP	0.05	12679
@NP	Fig. 3B	12686
@NP	2.4	12696
@NP	Quantitative analysis	12701
@NP	injured spinal crord by diffusion tensor imaging -LRB- DTI -RRB-	12730
@NP	injured spinal crord	12730
@NP	diffusion tensor imaging	12754
@NP	DTI	12780
@NP	FA	12806
@NP	a DTI quantitative parameter	12813
@NP	the axonal integrity and intensity	12856
@NP	Deboy et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005	12892
@NP	Deboy	12892
@NP	et al. , 2007 ; Kim et al. , 2007 ; Li et al. , 2015 ; Mukherjee , 2005	12898
@NP	et al. , 2007	12898
@NP	et al.	12898
@NP	2007	12906
@NP	Kim et al. , 2007	12912
@NP	Kim	12912
@NP	et al. , 2007	12916
@NP	et al.	12916
@NP	2007	12924
@NP	Li et al. , 2015	12930
@NP	Li	12930
@NP	et al. , 2015	12933
@NP	et al.	12933
@NP	2015	12941
@NP	Mukherjee , 2005	12947
@NP	Mukherjee	12947
@NP	2005	12958
@NP	FA values	12965
@NP	the lesion segment of spinal cord -LRB- Fig. 4 -RRB-	12994
@NP	the lesion segment	12994
@NP	spinal cord -LRB- Fig. 4 -RRB-	13016
@NP	spinal cord	13016
@NP	Fig. 4	13029
@NP	FA values	13038
@NP	there	13072
@NP	significant differences among three groups	13083
@NP	significant differences	13083
@NP	three groups	13113
@NP	the surgery -LRB- two-way ANOVA , p < 0.05 -RRB-	13132
@NP	the surgery	13132
@NP	two-way ANOVA , p < 0.05	13145
@NP	two-way ANOVA , p <	13145
@NP	two-way ANOVA	13145
@NP	p <	13160
@NP	p	13160
@NP	<	13162
@NP	0.05	13164
@NP	FA values of the high dose OEC-M group	13171
@NP	FA values	13171
@NP	the high dose OEC-M group	13184
@NP	the Con-M group	13241
@NP	all time points	13260
@NP	surgery -LRB- p < 0.05 -RRB-	13282
@NP	surgery	13282
@NP	p < 0.05	13291
@NP	p	13291
@NP	< 0.05	13293
@NP	<	13293
@NP	0.05	13295
@NP	There	13302
@NP	no significant difference between the low dose OEC-M group and the Con	13312
@NP	no significant difference	13312
@NP	the low dose OEC-M group and the Con	13346
@NP	the low dose OEC-M group	13346
@NP	the Con	13375
@NP	M group at week 1 post surgery	13384
@NP	M group	13384
@NP	week 1 post surgery	13395
@NP	differences between these two groups	13425
@NP	differences	13425
@NP	these two groups	13445
@NP	week 2	13496
@NP	week 6 -LRB- p < 0.05 -RRB-	13506
@NP	week 6	13506
@NP	p < 0.05	13514
@NP	p	13514
@NP	< 0.05	13516
@NP	<	13516
@NP	0.05	13518
@NP	FA values of the high dose OEC-M group	13535
@NP	FA values	13535
@NP	the high dose OEC-M group	13548
@NP	the low dose OEC-M group	13605
@NP	week 3 , week 4 , week 5 , and week 6 post surgery	13633
@NP	week 3	13633
@NP	week 4	13641
@NP	week 5	13649
@NP	week 6 post surgery	13661
@NP	2.5	13682
@NP	Repair process	13687
@NP	the injured spinal cord	13705
@NP	MRI and diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI	13741
@NP	MRI	13741
@NP	diffusion tensor tractography -LRB- DTT -RRB- Conventional MRI	13749
@NP	diffusion tensor tractography	13749
@NP	DTT	13780
@NP	Conventional MRI	13785
@NP	the T1-weighted images	13813
@NP	T1WI	13837
@NP	the T2-weighted images	13847
@NP	T2WI	13871
@NP	a 3.0 T MR scanner	13894
@NP	Signa , GE Medical Systems , Milwaukee , Wisconsin , USA	13914
@NP	Signa	13914
@NP	GE Medical Systems	13921
@NP	Milwaukee	13941
@NP	Wisconsin	13952
@NP	USA	13963
@NP	T1WI	13969
@NP	present noticeable changes	13981
@NP	the SCI -LRB- Fig. 5 -RRB-	14014
@NP	the SCI	14014
@NP	Fig. 5	14023
@NP	T2WI	14041
@NP	clear differences	14055
@NP	groups	14079
@NP	the repair process of SCI -LRB- Fig. 6 -RRB-	14089
@NP	the repair process	14089
@NP	SCI -LRB- Fig. 6 -RRB-	14111
@NP	SCI	14111
@NP	Fig. 6	14116
@NP	the contusion site of the spinal cord	14142
@NP	the contusion site	14142
@NP	the spinal cord	14164
@NP	there	14181
@NP	a region with decreased signal intensity surrounded by a hyperintense region	14191
@NP	a region	14191
@NP	decreased signal intensity surrounded by a hyperintense region	14205
@NP	decreased signal intensity	14205
@NP	a hyperintense region	14246
@NP	the systemic delivery of the treatments	14275
@NP	the systemic delivery	14275
@NP	the treatments	14300
@NP	T2WI of the low dose OEC-M group and the high dose OEC-M group	14316
@NP	T2WI	14316
@NP	the low dose OEC-M group and the high dose OEC-M group	14324
@NP	the low dose OEC-M group	14324
@NP	the high dose OEC-M group	14353
@NP	a shrinkage of the circumambient hyperintense regions	14388
@NP	a shrinkage	14388
@NP	the circumambient hyperintense regions	14403
@NP	the shrinkage	14447
@NP	the high dose OEC-M group	14481
@NP	the low dose OEC-M group at all time points	14512
@NP	the low dose OEC-M group	14512
@NP	all time points	14540
@NP	contrast to the OEC-M treated groups	14560
@NP	contrast	14560
@NP	the OEC-M treated groups	14572
@NP	the hyperintense region of the Con-M group	14598
@NP	the hyperintense region	14598
@NP	the Con-M group	14625
@NP	both rostral and caudal directions	14653
@NP	rostral	14658
@NP	caudal directions	14670
@NP	the injury site	14693
@NP	images of the Con-M group	14720
@NP	images	14720
@NP	the Con-M group	14730
@NP	an increased signal intensity of the hyperintense region over time	14759
@NP	an increased signal intensity	14759
@NP	the hyperintense region over time	14792
@NP	the hyperintense region	14792
@NP	time	14821
@NP	DTT	14827
@NP	the repair process of spinal cord tracts -LRB- Fig. 7 -RRB-	14862
@NP	the repair process	14862
@NP	spinal cord tracts -LRB- Fig. 7 -RRB-	14884
@NP	spinal cord tracts	14884
@NP	Fig. 7	14904
@NP	Results	14913
@NP	different characteristics of the nerve fiber	14931
@NP	different characteristics	14931
@NP	the nerve fiber	14960
@NP	different time points	14986
@NP	week 1 post surgery	15012
@NP	DTT of the spinal cord	15033
@NP	DTT	15033
@NP	the spinal cord	15040
@NP	the disruption of nerve tracks	15063
@NP	the disruption	15063
@NP	nerve tracks	15081
@NP	the edema of the spinal cord	15111
@NP	the edema	15111
@NP	the spinal cord	15124
@NP	depression of the white matter	15141
@NP	depression	15141
@NP	the white matter	15155
@NP	week 3	15192
@NP	injury	15205
@NP	there	15213
@NP	the irregularity of the nerve fiber	15233
@NP	the irregularity	15233
@NP	the nerve fiber	15253
@NP	clear depression at the injured site of spinal cord	15273
@NP	clear depression	15273
@NP	the injured site of spinal cord	15293
@NP	the injured site	15293
@NP	spinal cord	15313
@NP	The depression of the injury epicenter and the interruption of the fiber	15335
@NP	The depression of the injury epicenter	15335
@NP	The depression	15335
@NP	the injury epicenter	15353
@NP	the interruption of the fiber	15378
@NP	the interruption	15378
@NP	the fiber	15398
@NP	week 6	15427
@NP	surgery	15440
@NP	The tractography	15449
@NP	the OEC-M	15494
@NP	treated groups	15504
@NP	the depression	15520
@NP	the spinal cord at week 3 and week 6	15538
@NP	the spinal cord	15538
@NP	week 3 and week 6	15557
@NP	week 3	15557
@NP	week 6	15568
@NP	the distortion of nerve tracks after the contusive injury	15587
@NP	the distortion	15587
@NP	nerve tracks after the contusive injury	15605
@NP	nerve tracks	15605
@NP	the contusive injury	15624
@NP	the Con-M group	15665
@NP	no obvious reconnection of nerve fiber at the injury epicenter	15691
@NP	no obvious reconnection	15691
@NP	nerve fiber at the injury epicenter	15718
@NP	nerve fiber	15718
@NP	the injury epicenter	15733
@NP	the DTT images	15767
@NP	the treatment	15788
@NP	2.6	15803
@NP	Morphology of the lesion site	15808
@NP	Morphology	15808
@NP	the lesion site	15822
@NP	hematoxylin and eosin -LRB- HE -RRB-	15850
@NP	hematoxylin and eosin	15850
@NP	HE	15873
@NP	staining	15877
@NP	the magnification of 40	15889
@NP	the magnification	15889
@NP	40	15910
@NP	× , hematoxylin and eosin staining	15912
@NP	the morphologic changes of the lesion site -LRB- Fig. 8 -RRB-	15955
@NP	the morphologic changes	15955
@NP	the lesion site -LRB- Fig. 8 -RRB-	15982
@NP	the lesion site	15982
@NP	Fig. 8	15999
@NP	the contusion	16014
@NP	disorganization of the lesion site	16029
@NP	disorganization	16029
@NP	the lesion site	16048
@NP	infiltration of the inflammatory cells	16065
@NP	infiltration	16065
@NP	the inflammatory cells	16081
@NP	formation of the cavity	16105
@NP	formation	16105
@NP	the cavity	16118
@NP	the scar formation at the injury site	16133
@NP	the scar formation	16133
@NP	the injury site	16155
@NP	the HE	16189
@NP	all three groups	16208
@NP	week 1 post injury	16229
@NP	the differences of the morphologic changes at the lesion site	16249
@NP	the differences	16249
@NP	the morphologic changes at the lesion site	16268
@NP	the morphologic changes	16268
@NP	the lesion site	16295
@NP	three groups	16338
@NP	week 3	16364
@NP	the Con-M group	16384
@NP	the infiltration of cells	16401
@NP	the infiltration	16401
@NP	cells	16421
@NP	the injury site of OEC-M treated groups	16447
@NP	the injury site	16447
@NP	OEC-M treated groups	16466
@NP	week 6 post injury	16501
@NP	scar formation at the lesion site	16521
@NP	scar formation	16521
@NP	the lesion site	16539
@NP	the OEC-M treated groups , especially in the high dose OEC-M group	16575
@NP	the OEC-M treated groups , especially	16575
@NP	the OEC-M	16575
@NP	treated groups	16585
@NP	the high dose OEC-M group	16615
@NP	2.7	16642
@NP	Expression	16647
@NP	NF200	16661
@NP	immunohistochemistry	16681
@NP	The expression of NF200 of the injured spinal cord segment	16702
@NP	The expression	16702
@NP	NF200 of the injured spinal cord segment	16720
@NP	NF200	16720
@NP	the injured spinal cord segment	16729
@NP	immunohistochemistry	16779
@NP	A mouse anti-rat NF200 mono	16801
@NP	clonal antibody -LRB- 2 μg/ml , Abcam , Cambridge , MA , USA -RRB-	16830
@NP	clonal antibody	16830
@NP	2 μg/ml , Abcam , Cambridge , MA , USA	16847
@NP	2 μg/ml	16847
@NP	Abcam	16856
@NP	Cambridge	16863
@NP	MA	16874
@NP	USA	16878
@NP	a rabbit	16887
@NP	anti-mouse biotin-labeled antibody -LRB- Biosynthesis , Beijing , China -RRB-	16896
@NP	anti-mouse biotin-labeled antibody	16896
@NP	Biosynthesis	16932
@NP	Beijing	16946
@NP	China	16955
@NP	the primary and the secondary antibody	16978
@NP	the primary	16978
@NP	the secondary antibody	16994
@NP	sections	17034
@NP	there	17044
@NP	no axonal regeneration in the injury epicenter	17054
@NP	no axonal regeneration	17054
@NP	the injury epicenter	17080
@NP	the treatment -LRB- Fig. 9 -RRB-	17107
@NP	the treatment	17107
@NP	Fig. 9	17122
@NP	the results	17140
@NP	the Con-M	17179
@NP	OEC-M treatment	17190
@NP	the NF200 positive axonal regeneration	17218
@NP	the circumambient regions of the injury site -LRB- Fig. 10 -RRB-	17260
@NP	the circumambient regions	17260
@NP	the injury site -LRB- Fig. 10 -RRB-	17289
@NP	the injury site	17289
@NP	Fig. 10	17306
@NP	there	17320
@NP	more NF200	17331
@NP	positive structures	17342
@NP	the high dose OECM group than the low dose OEC-M group at all time points	17365
@NP	the high dose OECM group	17365
@NP	the low dose OEC-M group at all time points	17395
@NP	the low dose OEC-M group	17395
@NP	all time points	17423
@NP	the injury	17445
@NP	The NF200 positive density in the gray matter	17457
@NP	The NF200 positive density	17457
@NP	the gray matter	17487
@NP	Fig. 11	17520
@NP	Statistical results	17530
@NP	all three groups	17566
@NP	the NF200 positive density in the gray matter	17584
@NP	the NF200 positive density	17584
@NP	the gray matter	17614
@NP	week 3 and week 6 post injury	17657
@NP	week 3	17657
@NP	week 6 post injury	17668
@NP	p < 0.05	17688
@NP	p	17688
@NP	< 0.05	17690
@NP	<	17690
@NP	0.05	17692
@NP	There	17699
@NP	significant differences	17715
@NP	any two groups at all three time points -LRB- p < 0.05 -RRB-	17747
@NP	any two groups	17747
@NP	all three time points -LRB- p < 0.05 -RRB-	17765
@NP	all three time points	17765
@NP	p < 0.05	17788
@NP	p	17788
@NP	< 0.05	17790
@NP	<	17790
@NP	0.05	17792
@NP	Discussion Olfactory ensheathing cells	17803
@NP	OECs	17843
@NP	transplantation	17849
@NP	a promising candidate for the treatment of SCI	17874
@NP	a promising candidate	17874
@NP	the treatment of SCI	17900
@NP	the treatment	17900
@NP	SCI	17917
@NP	One of the highly recognized beneficial effects of OECs	17922
@NP	One	17922
@NP	the highly recognized beneficial effects of OECs	17929
@NP	the highly recognized beneficial effects	17929
@NP	OECs	17973
@NP	their expression of various neurotrophic factors	17981
@NP	their expression	17981
@NP	various neurotrophic factors	18001
@NP	extracellular matrix components	18034
@NP	BDNF , NGF , GDNF , Neurotrophin-4 /	18076
@NP	BDNF	18076
@NP	Neurotrophin-4	18093
@NP	5 -LRB- NT-4 / 5 -RRB-	18108
@NP	5	18108
@NP	NT-4	18111
@NP	neuregulin , secreted protein acidic rich in cysteine -LRB- SPARC -RRB-	18120
@NP	neuregulin	18120
@NP	protein acidic rich	18141
@NP	protein	18141
@NP	cysteine -LRB- SPARC -RRB-	18164
@NP	cysteine	18164
@NP	SPARC	18174
@NP	matrix metalloproteinase	18185
@NP	2 -LRB- MMP 2 -RRB-	18210
@NP	2	18210
@NP	MMP 2	18213
@NP	Au	18221
@NP	et al. , 2007	18224
@NP	et al.	18224
@NP	2007	18232
@NP	Lipson et al. , 2003	18238
@NP	Lipson	18238
@NP	et al. , 2003	18245
@NP	et al.	18245
@NP	2003	18253
@NP	Pastrana et al. , 2006	18259
@NP	Pastrana	18259
@NP	et al. , 2006	18268
@NP	et al.	18268
@NP	2006	18276
@NP	Richter and Roskanis , 2008	18282
@NP	Richter and Roskanis	18282
@NP	2008	18304
@NP	Woodhall et al. , 2001	18310
@NP	Woodhall	18310
@NP	et al. , 2001	18319
@NP	et al.	18319
@NP	2001	18327
@NP	the present study	18337
@NP	we	18356
@NP	a novel cell-free OECs	18376
@NP	therapy	18405
@NP	contusive spinal cord injury	18422
@NP	the consistent intraperitoneally injection of OEC-M	18454
@NP	the consistent intraperitoneally injection	18454
@NP	OEC-M	18500
@NP	the secretome of OECs	18520
@NP	the secretome	18520
@NP	OECs	18537
@NP	The results of this study	18543
@NP	The results	18543
@NP	this study	18558
@NP	the systemic delivery of OEC-M after SCI	18584
@NP	the systemic delivery	18584
@NP	OEC-M after SCI	18609
@NP	OEC-M	18609
@NP	SCI	18621
@NP	functional recovery	18634
@NP	axonal regeneration	18667
@NP	the injury epicenter	18694
@NP	the better therapeutic outcome	18726
@NP	the higher dose of OEC-M injection	18778
@NP	the higher dose	18778
@NP	OEC-M injection	18797
@NP	there	18829
@NP	no obvious axonal regeneration	18839
@NP	the epicenter of injury in the rats treated with OEC-M	18877
@NP	the epicenter	18877
@NP	injury in the rats treated with OEC-M	18894
@NP	injury	18894
@NP	the rats treated with OEC-M	18904
@NP	the rats	18904
@NP	OEC-M	18926
@NP	The therapeutic effects of OECs	18933
@NP	The therapeutic effects	18933
@NP	OECs	18960
@NP	the culture method , time in culture and purity of OECs	18995
@NP	the culture method	18995
@NP	time in culture and purity of OECs	19015
@NP	time	19015
@NP	culture and purity	19023
@NP	OECs	19045
@NP	It	19051
@NP	short-term cultured OECs purified with the method of differential cell adhesion	19074
@NP	short-term	19074
@NP	OECs purified with the method of differential cell adhesion	19094
@NP	OECs	19094
@NP	the method of differential cell adhesion	19113
@NP	the method	19113
@NP	differential cell adhesion	19127
@NP	better effects on the neural survival and axonal growth	19159
@NP	better effects	19159
@NP	the neural survival and axonal growth	19177
@NP	the neural survival	19177
@NP	axonal growth	19201
@NP	SCI -LRB- Novikova et al. , 2011 -RRB-	19221
@NP	SCI	19221
@NP	Novikova	19226
@NP	et al. , 2011	19235
@NP	et al.	19235
@NP	2011	19243
@NP	OECs age in culture	19259
@NP	OECs age	19259
@NP	culture	19271
@NP	their secretions	19280
@NP	example	19328
@NP	MMP 2 and SPARC that promote the neurite outgrowth and axonal regeneration	19337
@NP	MMP 2	19337
@NP	SPARC that promote the neurite outgrowth and axonal regeneration	19347
@NP	SPARC	19347
@NP	the neurite outgrowth and axonal regeneration	19366
@NP	the neurite outgrowth	19366
@NP	axonal regeneration	19392
@NP	late passage OECs -LRB- Au et al. , 2007 ; Pastrana et al. , 2006 -RRB-	19442
@NP	late passage OECs	19442
@NP	Au	19461
@NP	et al. , 2007 ; Pastrana et al. , 2006	19464
@NP	et al.	19464
@NP	2007 ; Pastrana et al.	19472
@NP	2007	19472
@NP	Pastrana et al.	19478
@NP	Pastrana	19478
@NP	et al.	19487
@NP	2006	19495
@NP	it	19512
@NP	4 -- 6 weeks in culture	19544
@NP	4	19544
@NP	6 weeks in culture	19546
@NP	6 weeks	19546
@NP	culture	19557
@NP	porcine OECs	19566
@NP	their phenotypic properties progressively -LRB- Radtke et al. , 2010 -RRB-	19605
@NP	their phenotypic properties progressively	19605
@NP	their phenotypic properties	19605
@NP	Radtke	19648
@NP	et al. , 2010	19655
@NP	et al.	19655
@NP	2010	19663
@NP	these , in the present study	19682
@NP	these	19682
@NP	the present study	19692
@NP	OECs	19711
@NP	postnatal day 2 rats	19736
@NP	postnatal day	19736
@NP	2 rats	19750
@NP	the differential cell adhesion method -LRB- Nash et al. , 2001 -RRB-	19770
@NP	the differential cell adhesion method	19770
@NP	Nash	19809
@NP	et al. , 2001	19814
@NP	et al.	19814
@NP	2001	19822
@NP	totally 2 weeks	19845
@NP	The purity of OECs	19862
@NP	The purity	19862
@NP	OECs	19876
@NP	more than 90 %	19902
@NP	the conditioned medium of OECs	19920
@NP	the conditioned medium	19920
@NP	OECs	19946
@NP	passage 1	19969
@NP	a previous research	19983
@NP	intraperitoneal injection of mice	20010
@NP	intraperitoneal injection	20010
@NP	mice	20039
@NP	embryonic stem cell conditioned medium	20044
@NP	embryonic stem cell	20044
@NP	ESC-M	20084
@NP	animals	20092
@NP	significant locomotor recovery	20109
@NP	SCI -LRB- Guo et al. , 2016 -RRB-	20146
@NP	SCI	20146
@NP	Guo	20151
@NP	et al. , 2016	20155
@NP	et al.	20155
@NP	2016	20163
@NP	accordance with that study	20173
@NP	accordance	20173
@NP	that study	20189
@NP	the functional benefit of OEC-M treatment in the present study	20201
@NP	the functional benefit	20201
@NP	OEC-M treatment in the present study	20227
@NP	OEC-M treatment	20227
@NP	the present study	20246
@NP	the BBB score	20281
@NP	It	20296
@NP	there	20319
@NP	no significant differences between high dose and low dose OEC-M groups	20330
@NP	no significant differences	20330
@NP	high dose and low dose OEC-M groups	20365
@NP	day 33	20404
@NP	day 42 post surgery	20414
@NP	contrast	20438
@NP	day 42 -LRB- week 6 -RRB-	20451
@NP	day 42	20451
@NP	week 6	20459
@NP	the injury	20473
@NP	the low dose OEC-M group	20497
@NP	the BDNF level in the high dose OEC-M group	20523
@NP	the BDNF level	20523
@NP	the high dose OEC-M group	20541
@NP	significant higher , as well as the NF200 positive density	20571
@NP	the NF200	20602
@NP	the gray matter	20632
@NP	This discrepancy	20649
@NP	the lordosis	20684
@NP	the laminectomy of T9 and T10 segments	20707
@NP	the laminectomy	20707
@NP	T9 and T10 segments	20726
@NP	artificial stabilization that hindered the plantar stepping	20754
@NP	artificial stabilization	20754
@NP	the plantar stepping	20793
@NP	the plantar	20793
@NP	the BBB score	20827
@NP	the NF200 immunohistochemistry staining	20852
@NP	the regeneration of axons	20907
@NP	the regeneration	20907
@NP	axons	20927
@NP	the area around the injury epicenter in all OEC-M treated groups	20951
@NP	the area	20951
@NP	the injury epicenter in all OEC-M treated groups	20967
@NP	the injury epicenter	20967
@NP	all OEC-M treated groups	20991
@NP	the functional recovery	21042
@NP	a certain extent	21069
@NP	the present study	21090
@NP	a major secretion of OECs	21112
@NP	a major secretion	21112
@NP	OECs	21133
@NP	the concentration of BDNF in peripheral blood	21139
@NP	the concentration	21139
@NP	BDNF in peripheral blood	21160
@NP	BDNF	21160
@NP	peripheral blood	21168
@NP	ELISA	21201
@NP	the secretome in the OEC-M	21218
@NP	the secretome	21218
@NP	the OEC-M	21235
@NP	the blood of animals	21279
@NP	the blood	21279
@NP	animals	21292
@NP	The ELISA results of our study	21301
@NP	The ELISA results	21301
@NP	our study	21322
@NP	the daily injection of OEC-M	21351
@NP	the daily injection	21351
@NP	OEC-M	21374
@NP	the BDNF concentrations	21381
@NP	the OEC-M treated groups , especially in the high dose group	21428
@NP	the OEC-M treated groups , especially	21428
@NP	the OEC-M	21428
@NP	treated groups	21438
@NP	the high dose group	21468
@NP	it	21498
@NP	BDNF	21528
@NP	the plasma and serum of different animals -LRB- Klein et al. , 2011 -RRB-	21552
@NP	the plasma and serum	21552
@NP	different animals -LRB- Klein et al. , 2011 -RRB-	21576
@NP	different animals	21576
@NP	Klein	21595
@NP	et al. , 2011	21601
@NP	et al.	21601
@NP	2011	21609
@NP	the Con-M that contained 10 % fetal bovine serum -LRB- FBS -RRB-	21637
@NP	the Con-M	21637
@NP	10 % fetal bovine serum -LRB- FBS -RRB-	21662
@NP	10 % fetal bovine serum	21662
@NP	FBS	21686
@NP	the BDNF levels in Con-M group	21692
@NP	the BDNF levels	21692
@NP	Con-M group	21711
@NP	Plasm BDNF levels in normal rats	21743
@NP	Plasm BDNF levels	21743
@NP	normal rats	21764
@NP	about 200 pg/ml	21795
@NP	Cahir et al. , 2008 ; Mannari et al. , 2008 ; Radka et al. , 1996	21812
@NP	Cahir	21812
@NP	et al. , 2008 ; Mannari et al. , 2008 ; Radka et al. , 1996	21818
@NP	et al. , 2008	21818
@NP	et al.	21818
@NP	2008	21826
@NP	Mannari et al. , 2008	21832
@NP	Mannari	21832
@NP	et al. , 2008	21840
@NP	et al.	21840
@NP	2008	21848
@NP	Radka et al. , 1996	21854
@NP	Radka	21854
@NP	et al. , 1996	21860
@NP	et al.	21860
@NP	1996	21868
@NP	the present study , the daily injection of OEC-M which contains 183.64 ±	21878
@NP	the present study	21878
@NP	the daily injection of OEC-M which contains 183.64 ±	21897
@NP	the daily injection	21897
@NP	OEC-M	21920
@NP	183.64 ±	21941
@NP	12.61 pg/ml BDNF	21950
@NP	the plasma BDNF concentrations	21977
@NP	300 pg/ml at 6 weeks	22017
@NP	300 pg/ml	22017
@NP	6 weeks	22030
@NP	surgery	22044
@NP	previous study	22066
@NP	the blood-spinal cord barrier -LRB- BSCB -RRB-	22082
@NP	the blood-spinal cord barrier	22082
@NP	BSCB	22113
@NP	5 mins	22139
@NP	the mechanical trauma	22152
@NP	spinal cord injury -LRB- Maikos and Shreiber , 2007 -RRB-	22177
@NP	spinal cord injury	22177
@NP	Maikos and Shreiber , 2007	22197
@NP	Maikos	22197
@NP	Shreiber , 2007	22208
@NP	Shreiber	22208
@NP	2007	22218
@NP	the disruption of BSCB	22228
@NP	the disruption	22228
@NP	BSCB	22246
@NP	28 days -LRB- Popovich et al. , 1996 -RRB-	22263
@NP	28 days	22263
@NP	Popovich	22272
@NP	et al. , 1996	22281
@NP	et al.	22281
@NP	1996	22289
@NP	the time course of the re-establishment of BSCB function	22307
@NP	the time course	22307
@NP	the re-establishment of BSCB function	22326
@NP	the re-establishment	22326
@NP	BSCB function	22350
@NP	varying results	22384
@NP	Noble and Wrathall , 1989 ; Popovich et al. , 1996	22414
@NP	Noble and Wrathall	22414
@NP	1989 ; Popovich et al.	22434
@NP	1989	22434
@NP	Popovich et al.	22440
@NP	Popovich	22440
@NP	et al.	22449
@NP	1996	22457
@NP	the MRI and immunohistochemistry	22486
@NP	the MRI	22486
@NP	immunohistochemistry	22498
@NP	the BSCB	22520
@NP	day 56	22557
@NP	traumatic SCI -LRB- Cohen et al. , 2009 -RRB-	22570
@NP	traumatic SCI	22570
@NP	Cohen	22585
@NP	et al. , 2009	22591
@NP	et al.	22591
@NP	2009	22599
@NP	these facts	22618
@NP	the absorbed BDNF	22631
@NP	the blood	22652
@NP	other neurotrophic factors and extracellular matrix components	22674
@NP	other neurotrophic factors	22674
@NP	extracellular matrix components	22705
@NP	the OEC-M	22742
@NP	the injured spinal cord	22773
@NP	the compromised BSCB	22805
@NP	their beneficial effects	22838
@NP	DTI	22864
@NP	a quantitative measurement	22871
@NP	the diffusion of water molecules in three dimensions	22907
@NP	the diffusion	22907
@NP	water molecules in three dimensions	22924
@NP	water molecules	22924
@NP	three dimensions	22943
@NP	Axonal membranes and myelin	22961
@NP	Axonal membranes	22961
@NP	myelin	22982
@NP	the water diffusion	23020
@NP	the axon tracts	23047
@NP	DTI	23076
@NP	the pathophysiology	23100
@NP	the nervous system -LRB- Basser , 1995 ; Beaulieu and Allen , 1994 -RRB-	23123
@NP	the nervous system	23123
@NP	Basser , 1995 ; Beaulieu and Allen , 1994	23143
@NP	Basser	23143
@NP	1995 ; Beaulieu and Allen	23151
@NP	1995	23151
@NP	Beaulieu and Allen	23157
@NP	1994	23177
@NP	the conventional MRI	23196
@NP	DTI parameters	23218
@NP	the pathophysiology processes	23280
@NP	the severity	23325
@NP	injury	23341
@NP	contusive SCI	23358
@NP	Kelley	23373
@NP	et al. , 2014	23380
@NP	et al.	23380
@NP	2014	23388
@NP	Konomi et al. , 2012	23394
@NP	Konomi	23394
@NP	et al. , 2012	23401
@NP	et al.	23401
@NP	2012	23409
@NP	Li et al. , 2015	23415
@NP	Li	23415
@NP	et al. , 2015	23418
@NP	et al.	23418
@NP	2015	23426
@NP	Loy et al. , 2007	23432
@NP	Loy	23432
@NP	et al. , 2007	23436
@NP	et al.	23436
@NP	2007	23444
@NP	Patel et al. , 2016	23450
@NP	Patel	23450
@NP	et al. , 2016	23456
@NP	et al.	23456
@NP	2016	23464
@NP	FA value , which reflects the anisotropy of the diffusion ,	23471
@NP	FA value	23471
@NP	the anisotropy of the diffusion	23496
@NP	the anisotropy	23496
@NP	the diffusion	23514
@NP	the most frequently used DTI parameter	23532
@NP	the SCI	23578
@NP	FA values of the injured regions	23587
@NP	FA values	23587
@NP	the injured regions	23600
@NP	Konomi et al. , 2012 ; Li et al. , 2015 ; Rajasekaran et al. , 2012	23649
@NP	Konomi	23649
@NP	et al. , 2012 ; Li et al. , 2015 ; Rajasekaran et al. , 2012	23656
@NP	et al. , 2012	23656
@NP	et al.	23656
@NP	2012	23664
@NP	Li et al. , 2015	23670
@NP	Li	23670
@NP	et al. , 2015	23673
@NP	et al.	23673
@NP	2015	23681
@NP	Rajasekaran et al. , 2012	23687
@NP	Rajasekaran	23687
@NP	et al. , 2012	23699
@NP	et al.	23699
@NP	2012	23707
@NP	the reduced FA values	23717
@NP	nerve degeneration	23759
@NP	axonal loss -LRB- Deboy et al. , 2007 ; Mukherjee , 2005 -RRB-	23782
@NP	axonal loss	23782
@NP	Deboy	23795
@NP	et al. , 2007 ; Mukherjee , 2005	23801
@NP	et al.	23801
@NP	2007 ; Mukherjee	23809
@NP	2007	23809
@NP	Mukherjee	23815
@NP	2005	23826
@NP	the present study	23836
@NP	our data	23855
@NP	the OEC-M treatment	23876
@NP	the FA values and the higher FA value	23916
@NP	the FA values	23916
@NP	the higher FA value	23934
@NP	higher dose of OEC-M injection	23975
@NP	higher dose	23975
@NP	OEC-M injection	23990
@NP	These results	24007
@NP	the administration of OEC-M	24031
@NP	the administration	24031
@NP	OEC-M	24053
@NP	SCI	24065
@NP	the nerve regeneration	24083
@NP	the axons	24119
@NP	the injury segment	24132
@NP	the FA value	24161
@NP	the whole transverse section of the injured spinal cord segment	24192
@NP	the whole transverse section	24192
@NP	the injured spinal cord segment	24224
@NP	the regeneration of axons in the area around the injury epicenter	24265
@NP	the regeneration	24265
@NP	axons in the area around the injury epicenter	24285
@NP	axons	24285
@NP	the area around the injury epicenter	24294
@NP	the area	24294
@NP	the injury epicenter	24310
@NP	the increase of FA values	24348
@NP	the increase	24348
@NP	FA values	24364
@NP	Conventional MRI	24375
@NP	the repair process of the injured spinal cord	24417
@NP	the repair process	24417
@NP	the injured spinal cord	24439
@NP	our study	24467
@NP	T1WI	24478
@NP	significant signal changes	24498
@NP	SCI	24531
@NP	T2WI , which is known to detect edema and hemorrhage ,	24547
@NP	T2WI	24547
@NP	edema and hemorrhage	24578
@NP	obvious differences	24609
@NP	different time points	24632
@NP	the SCI	24660
@NP	1 week after SCI	24672
@NP	1 week	24672
@NP	SCI	24685
@NP	the hypointense regions at the injury epicenter	24690
@NP	the hypointense regions	24690
@NP	the injury epicenter	24717
@NP	the hemorrhage	24748
@NP	the spinal cord	24770
@NP	the hyperintense region around the injury epicenter	24790
@NP	the hyperintense region	24790
@NP	the injury epicenter	24821
@NP	the segmental edema	24860
@NP	Kawakyu-O ′ Connor et al. , 2016 ; Kumar and Hayashi , 2016	24881
@NP	Kawakyu-O ′ Connor	24881
@NP	et al. , 2016 ; Kumar and Hayashi , 2016	24898
@NP	et al. , 2016	24898
@NP	et al.	24898
@NP	2016	24906
@NP	Kumar and Hayashi , 2016	24912
@NP	Kumar and Hayashi	24912
@NP	2016	24931
@NP	the late time point -LRB- 3 week and 6 week -RRB- after injury	24950
@NP	the late time point -LRB- 3 week and 6 week -RRB-	24950
@NP	the late time point	24950
@NP	3 week and 6 week	24971
@NP	3 week	24971
@NP	6 week	24982
@NP	injury	24996
@NP	the hyperintense regions	25004
@NP	the hyperintense	25004
@NP	regions	25021
@NP	malacia	25050
@NP	Our results	25059
@NP	contrast	25087
@NP	the shrinkage of the hyperintense regions	25099
@NP	the shrinkage	25099
@NP	the hyperintense regions	25116
@NP	OEC-M treated group	25144
@NP	the hyperintense region	25165
@NP	the Con-M group	25192
@NP	both rostral and caudal directions	25220
@NP	rostral	25225
@NP	caudal directions	25237
@NP	the injury site	25260
@NP	This extension	25277
@NP	the secondary injury process	25302
@NP	the initial trauma	25337
@NP	spinal cord	25359
@NP	Ambrozaitis et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997	25372
@NP	Ambrozaitis	25372
@NP	et al. , 2006 ; Dumont et al. , 2001 ; Popovich et al. , 1997	25384
@NP	et al. , 2006	25384
@NP	et al.	25384
@NP	2006	25392
@NP	Dumont et al. , 2001	25398
@NP	Dumont	25398
@NP	et al. , 2001	25405
@NP	et al.	25405
@NP	2001	25413
@NP	Popovich et al. , 1997	25419
@NP	Popovich	25419
@NP	et al. , 1997	25428
@NP	et al.	25428
@NP	1997	25436
@NP	these	25455
@NP	the results of T2WI	25462
@NP	the results	25462
@NP	T2WI	25477
@NP	the OEC-M treatment	25495
@NP	the malacia	25523
@NP	the secondary injury following the initial trauma of the spinal cord	25550
@NP	the secondary injury	25550
@NP	the initial trauma of the spinal cord	25581
@NP	the initial trauma	25581
@NP	the spinal cord	25603
@NP	It	25620
@NP	DTT	25646
@NP	the injury epicenter	25663
@NP	the interrupted nerve fiber	25701
@NP	the intact tracts	25734
@NP	various types of SCI -LRB- Li et al. , 2015 ; Wang et al. , 2014 -RRB-	25758
@NP	various types	25758
@NP	SCI -LRB- Li et al. , 2015 ; Wang et al. , 2014 -RRB-	25775
@NP	SCI	25775
@NP	Li	25780
@NP	et al. , 2015 ; Wang et al. , 2014	25783
@NP	et al.	25783
@NP	2015 ; Wang et al.	25791
@NP	2015	25791
@NP	Wang et al.	25797
@NP	Wang	25797
@NP	et al.	25802
@NP	2014	25810
@NP	DTT	25828
@NP	the repair process of injured spinal cord	25865
@NP	the repair process	25865
@NP	injured spinal cord	25887
@NP	various kinds of interventions -LRB- Konomi et al. , 2012 -RRB-	25913
@NP	various kinds	25913
@NP	interventions -LRB- Konomi et al. , 2012 -RRB-	25930
@NP	interventions	25930
@NP	Konomi	25945
@NP	et al. , 2012	25952
@NP	et al.	25952
@NP	2012	25960
@NP	the present study	25970
@NP	DTT	25989
@NP	the overall shape of the contusive injury epicenter	26002
@NP	the overall shape	26002
@NP	the contusive injury epicenter	26023
@NP	the depression of the spinal cord and the distortion of the nerve tracks	26068
@NP	the depression of the spinal cord	26068
@NP	the depression	26068
@NP	the spinal cord	26086
@NP	the distortion of the nerve tracks	26106
@NP	the distortion	26106
@NP	the nerve tracks	26124
@NP	The tractography	26142
@NP	the OEC-M treatment	26169
@NP	the axonal regeneration	26210
@NP	the lesion epicenter	26241
@NP	accordance with our immunohistochemistry results	26276
@NP	accordance	26276
@NP	our immunohistochemistry results	26292
@NP	our results	26335
@NP	depression of the injured spinal cord and interruption of the nerve fibers	26365
@NP	depression	26365
@NP	the injured spinal cord and interruption of the nerve fibers	26379
@NP	the injured spinal cord	26379
@NP	interruption of the nerve fibers	26407
@NP	interruption	26407
@NP	the nerve fibers	26423
@NP	the OEC-M treatment	26459
@NP	previous studies	26493
@NP	the expression of various neurotrophic factors	26519
@NP	the expression	26519
@NP	various neurotrophic factors	26537
@NP	the transplanted OECs	26567
@NP	their beneficial effects	26595
@NP	the interaction with the astrocytes and neurons	26623
@NP	the interaction	26623
@NP	the astrocytes and neurons	26644
@NP	their bridging	26683
@NP	their	26683
@NP	migration	26702
@NP	the lesion site	26719
@NP	Chuah	26736
@NP	et al. , 2011	26742
@NP	et al.	26742
@NP	2011	26750
@NP	Chung et al. , 2004	26756
@NP	Chung	26756
@NP	et al. , 2004	26762
@NP	et al.	26762
@NP	2004	26770
@NP	Deng et al. , 2006	26776
@NP	Deng	26776
@NP	et al. , 2006	26781
@NP	et al.	26781
@NP	2006	26789
@NP	Pearse et al. , 2007	26795
@NP	Pearse	26795
@NP	et al. , 2007	26802
@NP	et al.	26802
@NP	2007	26810
@NP	Sasaki et al. , 2004	26816
@NP	Sasaki	26816
@NP	et al. , 2004	26823
@NP	et al.	26823
@NP	2004	26831
@NP	our hypothesis	26841
@NP	the low survival rate of grafted cells	26864
@NP	the low survival rate	26864
@NP	grafted cells	26889
@NP	only a small number of transplanted OECs	26904
@NP	only a small number	26904
@NP	transplanted OECs	26927
@NP	the bridging and migration effects during a relatively short period post injury	26970
@NP	the bridging and migration effects	26970
@NP	a relatively short period post injury	27012
@NP	there	27061
@NP	studies	27076
@NP	the grafted OECs	27096
@NP	migratory property -LRB- Lu et al. , 2006 ; Pearse et al. , 2007 -RRB-	27128
@NP	migratory property	27128
@NP	Lu	27148
@NP	et al. , 2006 ; Pearse et al. , 2007	27151
@NP	et al.	27151
@NP	2006 ; Pearse et al.	27159
@NP	2006	27159
@NP	Pearse et al.	27165
@NP	Pearse	27165
@NP	et al.	27172
@NP	2007	27180
@NP	this	27199
@NP	we	27205
@NP	the cell-free OEC-M treatment	27216
@NP	the beneficial effects of neurotrophic factors	27262
@NP	the beneficial effects	27262
@NP	neurotrophic factors	27288
@NP	the limitation	27326
@NP	cell survival , immune rejection and cell transplantation surgery	27344
@NP	cell survival	27344
@NP	immune rejection	27359
@NP	cell transplantation surgery	27380
@NP	the recovery of SCI	27424
@NP	the recovery	27424
@NP	SCI	27440
@NP	the present study	27448
@NP	the HE staining	27467
@NP	HE	27471
@NP	the pathological changes	27492
@NP	the OEC-M treatment	27523
@NP	the OEC-M groups	27547
@NP	the infiltration of cells and the scar formation at the lesion site	27565
@NP	the infiltration	27565
@NP	cells and the scar formation at the lesion site	27585
@NP	cells	27585
@NP	the scar formation at the lesion site	27595
@NP	the scar formation	27595
@NP	the lesion site	27617
@NP	the Con-M group	27656
@NP	Our NF200 immunohistochemistry staining	27673
@NP	axons and dendrites -LRB- Grady et al. , 1993 -RRB-	27740
@NP	axons and dendrites	27740
@NP	Grady	27761
@NP	et al. , 1993	27767
@NP	et al.	27767
@NP	1993	27775
@NP	the OEC-M treatment	27797
@NP	the axonal regeneration	27826
@NP	the lesion epicenter	27857
@NP	NF200 staining	27888
@NP	there	27915
@NP	no obvious axonal regeneration across the injury epicenter	27925
@NP	no obvious axonal regeneration	27925
@NP	the injury epicenter	27963
@NP	this	27988
@NP	the glial scar	28011
@NP	the astrocytes that eventually blocks the axonal penetration	28036
@NP	the astrocytes	28036
@NP	the axonal penetration	28074
@NP	conclusion	28101
@NP	the present study	28113
@NP	the systemic delivery of olfactory ensheathing cells conditioned medium	28144
@NP	the systemic delivery	28144
@NP	olfactory ensheathing cells conditioned medium	28169
@NP	olfactory ensheathing cells	28169
@NP	the recovery of contusive SCI	28225
@NP	the recovery	28225
@NP	contusive SCI	28241
@NP	the functional recovery	28268
@NP	axonal regeneration	28309
@NP	This novel cell-free OEC based therapy	28330
@NP	This novel cell-free OEC	28330
@NP	therapy	28361
@NP	the traditional limitations of OEC transplantation	28381
@NP	the traditional limitations	28381
@NP	OEC transplantation	28412
@NP	new possibilities for the future clinical applications	28444
@NP	new possibilities	28444
@NP	the future clinical applications	28466
@NP	SCI	28502
@NP	better axonal regeneration	28545
@NP	the specific factors	28585
@NP	these changes	28622
@NP	Materials and methods This study	28641
@NP	Materials	28641
@NP	methods This study	28655
@NP	methods	28655
@NP	This study	28663
@NP	the approval	28693
@NP	the Biomedical Ethics Committee of Medical College of Xi'an Jiaotong University	28709
@NP	the Biomedical Ethics Committee	28709
@NP	Medical College of Xi'an Jiaotong University	28744
@NP	Medical College	28744
@NP	Xi'an Jiaotong University	28763
@NP	The animal care and the experimental procedures	28790
@NP	The animal care	28790
@NP	the experimental procedures	28810
@NP	strict accordance	28856
@NP	the guidelines established by the National Institutes of Health	28879
@NP	the guidelines	28879
@NP	the National Institutes of Health	28909
@NP	the National Institutes	28909
@NP	Health	28936
@NP	4.1	28944
@NP	Culture and identification	28949
@NP	OECs Following the procedures of Nash et al. , Olfactory bulbs	28979
@NP	OECs	28979
@NP	the procedures of Nash et al. , Olfactory bulbs	28994
@NP	the procedures	28994
@NP	Nash	29012
@NP	et al. , Olfactory bulbs	29017
@NP	et al.	29017
@NP	Olfactory bulbs	29025
@NP	2-D-old rats	29071
@NP	cold Hank 's balanced salt solution	29098
@NP	cold Hank 's	29098
@NP	HBSS	29134
@NP	Invitrogen , Carlsbad	29140
@NP	CA , USA	29162
@NP	The meninges and blood vessels	29172
@NP	fine forceps	29222
@NP	microscope and the olfactory nerve	29241
@NP	microscope	29241
@NP	the olfactory nerve	29256
@NP	glomerular layers	29280
@NP	small pieces	29318
@NP	0.25 % trypsin -LRB- Sigma -RRB-	29369
@NP	0.25 % trypsin	29369
@NP	Sigma	29384
@NP	5 min at 37 °C and 5 % CO2	29395
@NP	5 min at 37 °C	29395
@NP	5 min	29395
@NP	37 °C	29404
@NP	5 % CO2	29414
@NP	the termination	29428
@NP	digestion by adding 10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29447
@NP	digestion	29447
@NP	10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29467
@NP	10 % fetal bovine serum	29467
@NP	FBS	29491
@NP	Gibco	29496
@NP	the solution	29504
@NP	1000 rpm for 5 min	29536
@NP	1000 rpm	29536
@NP	5 min	29549
@NP	the supernatant	29559
@NP	The culture medium	29590
@NP	DF-12 medium -LRB- 1:1 mixture of DMEM and Ham 's F-12 -RRB-	29623
@NP	DF-12 medium	29623
@NP	1:1 mixture of DMEM and Ham 's F-12	29637
@NP	1:1 mixture	29637
@NP	DMEM and Ham 's F-12	29652
@NP	DMEM	29652
@NP	Ham 's F-12	29661
@NP	Ham 's	29661
@NP	10 % fetal bovine serum	29674
@NP	1 % penicillin-streptomycin -LRB- Sigma -RRB-	29701
@NP	1 % penicillin-streptomycin	29701
@NP	Sigma	29729
@NP	the cell pellet	29759
@NP	The cells	29776
@NP	culture flasks	29803
@NP	25 cm2 , Nunclon , Thermo Scientific , Waltham , MA , USA	29819
@NP	25 cm2	29819
@NP	Nunclon	29827
@NP	Thermo Scientific	29836
@NP	Waltham	29855
@NP	MA	29864
@NP	USA	29868
@NP	differential attachment culture	29877
@NP	Nash	29922
@NP	et al. -LRB- 2001 -RRB-	29927
@NP	et al.	29927
@NP	2001	29935
@NP	the primary OECs	29951
@NP	purification and primary culture for 7 days	29975
@NP	purification and primary culture	29975
@NP	7 days	30012
@NP	cells	30020
@NP	slides coated with poly-L-lysine for immunofluorescence analysis	30059
@NP	slides	30059
@NP	poly-L-lysine for immunofluorescence analysis	30078
@NP	poly-L-lysine	30078
@NP	immunofluorescence analysis	30096
@NP	the attachment	30131
@NP	cells	30147
@NP	phosphate-buffered saline -LRB- PBS -RRB-	30168
@NP	phosphate-buffered saline	30168
@NP	PBS	30195
@NP	4 % PFA for 20 min	30222
@NP	4 % PFA	30222
@NP	20 min	30233
@NP	Non-specific protein binding	30241
@NP	a 60 min incubation	30285
@NP	10 % goat serum albumin -LRB- Sigma -RRB-	30310
@NP	10 % goat serum albumin	30310
@NP	Sigma	30334
@NP	room temperature	30344
@NP	Cells	30362
@NP	4 ℃	30396
@NP	a rabbit anti-rat P75NTR monoclonal antibody	30405
@NP	a rabbit anti-rat P75NTR	30405
@NP	1:50 Proteintech , Chicago , IL , USA	30451
@NP	1:50 Proteintech , Chicago	30451
@NP	IL	30478
@NP	USA	30482
@NP	a 15 min wash in PBS	30500
@NP	a 15 min wash	30500
@NP	PBS	30517
@NP	Goat anti-rabbit antibody	30522
@NP	DyLight 488 -LRB- 1 ; 500 , Boster , China -RRB-	30548
@NP	DyLight 488	30548
@NP	1 ; 500 , Boster , China	30561
@NP	1 ; 500	30561
@NP	Boster , China	30568
@NP	the secondary antibody and the cells	30595
@NP	the secondary antibody	30595
@NP	the cells	30622
@NP	60 min at room temperature	30651
@NP	60 min	30651
@NP	room temperature	30661
@NP	a 15 min wash in PBS	30685
@NP	a 15 min wash	30685
@NP	PBS	30702
@NP	DAPI -LRB- 100 ng/ml -RRB-	30707
@NP	DAPI	30707
@NP	100 ng/ml	30713
@NP	10 min at room temperature	30738
@NP	10 min	30738
@NP	room temperature	30748
@NP	cells	30772
@NP	50 % glycerol	30794
@NP	Random areas	30808
@NP	the percentage of P75 positive cells	30843
@NP	the percentage	30843
@NP	P75 positive cells	30861
@NP	4.2	30894
@NP	Preparation of OEC conditioned medium	30899
@NP	Preparation	30899
@NP	OEC conditioned medium	30914
@NP	the purification and primary culture of OECs for 7 days	30943
@NP	the purification and primary culture	30943
@NP	OECs for 7 days	30983
@NP	OECs	30983
@NP	7 days	30992
@NP	cells	31000
@NP	the culture medium described above	31042
@NP	the culture medium	31042
@NP	The medium	31078
@NP	every two days	31101
@NP	the cell supernatant	31120
@NP	day 4 and day 6	31158
@NP	day 4	31158
@NP	day 6	31168
@NP	the subculturing	31180
@NP	These supernatants	31198
@NP	2500 rpm for 10 min	31237
@NP	2500 rpm	31237
@NP	10 min	31250
@NP	4 ℃	31260
@NP	a 0.4 μm filter	31290
@NP	debris	31316
@NP	The supernatant	31324
@NP	the OEC conditioned medium -LRB- OEC-M -RRB-	31358
@NP	the OEC conditioned medium	31358
@NP	OEC-M	31386
@NP	− 80 ℃	31407
@NP	The culture medium -LRB- without OECs -RRB-	31425
@NP	The culture medium	31425
@NP	OECs	31452
@NP	the control medium -LRB- Con-M -RRB-	31470
@NP	the control medium	31470
@NP	Con-M	31490
@NP	4.3	31498
@NP	Spinal cord surgery A total	31503
@NP	54 healthy adult male Sprague-Dawley rats weighing between 250 and 300 g	31534
@NP	54 healthy adult male Sprague-Dawley rats	31534
@NP	between 250 and 300 g	31585
@NP	preoperative environmental adaption for 2 weeks with free access	31620
@NP	preoperative environmental adaption	31620
@NP	2 weeks with free access	31660
@NP	2 weeks	31660
@NP	free access	31673
@NP	food and water	31688
@NP	room temperature	31706
@NP	Rats	31724
@NP	intraperitoneal injection of sodium pentobarbital	31752
@NP	intraperitoneal injection	31752
@NP	sodium pentobarbital	31781
@NP	40 mg/kg body weight	31805
@NP	The laminectomy	31827
@NP	T9-10	31865
@NP	the spinal cord	31881
@NP	The spinal cord injury	31898
@NP	T10 segment	31935
@NP	the NYU weight-drop impactor -LRB- New York University , New York , USA -RRB-	31953
@NP	the NYU weight-drop impactor	31953
@NP	New York University	31983
@NP	New York	32004
@NP	USA	32014
@NP	a 10 g rod	32024
@NP	a height of 25.0 mm	32048
@NP	a height	32048
@NP	25.0 mm	32060
@NP	Hemorrhage and edema	32069
@NP	the injured area , as well as the tail wagging and hind limb fluttering	32093
@NP	the injured area	32093
@NP	the tail wagging and hind limb fluttering	32122
@NP	the tail wagging	32122
@NP	hind limb fluttering	32143
@NP	the successful modeling of contusive spinal cord injury	32175
@NP	the successful modeling	32175
@NP	contusive spinal cord injury	32202
@NP	the muscles and skins	32244
@NP	separate layers	32282
@NP	Gentamicin -LRB- 5 mg/kg -RRB-	32299
@NP	Gentamicin	32299
@NP	5 mg/kg	32311
@NP	the surgery	32361
@NP	7 days	32392
@NP	Buprenorphine -LRB- 0.01 mg/kg -RRB-	32403
@NP	Buprenorphine	32403
@NP	0.01 mg/kg	32418
@NP	subcutaneous injection for 3 days	32473
@NP	subcutaneous injection	32473
@NP	3 days	32500
@NP	Rats	32508
@NP	free access	32534
@NP	food and water	32549
@NP	manual bladder evacuation	32577
@NP	twice every day	32603
@NP	normal function	32625
@NP	4.4	32651
@NP	Treatment groups and BBB scores	32656
@NP	Treatment groups	32656
@NP	BBB scores	32677
@NP	the study of treatment effects	32692
@NP	the study	32692
@NP	treatment effects	32705
@NP	the animals	32724
@NP	Con-M group -LRB- n = 18 -RRB-	32754
@NP	Con-M group	32754
@NP	n	32767
@NP	18	32769
@NP	low-dose OEC-M group -LRB- n = 18 -RRB-	32774
@NP	low-dose OEC-M group	32774
@NP	n	32796
@NP	18	32798
@NP	high-dose OEC-M group -LRB- n = 18 -RRB-	32807
@NP	high-dose OEC-M group	32807
@NP	n	32830
@NP	18	32832
@NP	Different reagents	32837
@NP	rat	32899
@NP	surgery	32915
@NP	the rats	32929
@NP	The rats in the Con-M group	32955
@NP	The rats	32955
@NP	the Con-M group	32967
@NP	2 ml Con-M	33002
@NP	2 ml mixed medium -LRB- 1 ml OEC-M and 1 ml Con-M -RRB- and 2 ml OEC-M	33025
@NP	2 ml mixed medium -LRB- 1 ml OEC-M and 1 ml Con-M -RRB-	33025
@NP	2 ml mixed medium	33025
@NP	2 ml	33025
@NP	1 ml OEC-M and 1 ml Con-M	33044
@NP	1 ml OEC-M	33044
@NP	1 ml Con-M	33059
@NP	2 ml OEC-M	33075
@NP	the rats in the low-dose OEC-M group and high-dose OEC-M group	33102
@NP	the rats	33102
@NP	the low-dose OEC-M group and high-dose OEC-M group	33114
@NP	the low-dose OEC-M group	33114
@NP	high-dose OEC-M group	33143
@NP	The Basso , Beattie and Bresnahan	33179
@NP	BBB	33213
@NP	scores -LRB- Basso et al. , 1995 -RRB-	33218
@NP	scores	33218
@NP	Basso	33226
@NP	et al. , 1995	33232
@NP	et al.	33232
@NP	1995	33240
@NP	two independent and blinded observers	33264
@NP	every three days	33302
@NP	the surgery until sacrificed	33325
@NP	the surgery	33325
@NP	4.5	33355
@NP	MRI , DTI	33360
@NP	DTT	33373
@NP	Eighteen rats -LRB- Six rats per group -RRB-	33382
@NP	Eighteen rats	33382
@NP	Six rats per group	33397
@NP	Six rats	33397
@NP	group	33410
@NP	the diffusion tensor imaging	33444
@NP	DTI	33474
@NP	every week	33484
@NP	the surgery	33501
@NP	Conventional MRI	33514
@NP	day 7 , 21 and 42 post surgery	33549
@NP	day 7	33549
@NP	21	33556
@NP	42 post surgery	33563
@NP	The animals	33580
@NP	sodium pentobarbital	33615
@NP	40 mg/kg	33637
@NP	a supine position within a specialized coil designed for scanning rats	33666
@NP	a supine position	33666
@NP	a specialized coil designed for scanning rats	33691
@NP	a specialized coil	33691
@NP	scanning rats	33723
@NP	All the scans	33738
@NP	a 3.0 T MR scanner	33778
@NP	Signa , GE Medical Systems , Milwaukee , Wisconsin , USA	33798
@NP	Signa	33798
@NP	GE Medical Systems	33805
@NP	Milwaukee	33825
@NP	Wisconsin	33836
@NP	USA	33847
@NP	SE sequence	33853
@NP	the conventional MRI	33886
@NP	T1-weighted and T2-weighted images	33928
@NP	single shot spinecho planar imaging -LRB- EPI -RRB- sequence	33968
@NP	single shot spinecho planar imaging -LRB- EPI -RRB-	33968
@NP	sequence	34010
@NP	the DTI images	34042
@NP	The relevant parameters for conventional MRI and DTI of this study	34058
@NP	The relevant parameters	34058
@NP	conventional MRI and DTI	34086
@NP	this study	34114
@NP	strict accordance with Li	34133
@NP	strict accordance	34133
@NP	Li	34156
@NP	et al. -LRB- 2015 -RRB-	34159
@NP	et al.	34159
@NP	2015	34167
@NP	the	34180
@NP	the data	34190
@NP	a separate workstation	34219
@NP	Advantage windows workstation	34243
@NP	version 4.2	34274
@NP	GE Healthcare	34287
@NP	Waukesha	34302
@NP	Wisconsin	34312
@NP	USA	34323
@NP	the quantitative DTI parameter -LRB- FA value -RRB-	34341
@NP	the quantitative DTI parameter	34341
@NP	FA value	34373
@NP	Diffusion tensor tractography -LRB- DTT -RRB- of the injury site	34384
@NP	Diffusion tensor tractography -LRB- DTT -RRB-	34384
@NP	Diffusion tensor tractography	34384
@NP	DTT	34415
@NP	the injury site	34423
@NP	the FuncTool software -LRB- GE Healthcare -RRB-	34463
@NP	the FuncTool software	34463
@NP	GE Healthcare	34486
@NP	4.6	34502
@NP	Perfusion and tissue processing Rats	34507
@NP	7	34583
@NP	21 and 42 days	34586
@NP	the MRI and DTI	34607
@NP	n = 18 for each time point , 6 rats per group	34629
@NP	n = 18	34629
@NP	n	34629
@NP	18	34632
@NP	each time point , 6 rats per group	34639
@NP	each time point	34639
@NP	6 rats per group	34656
@NP	6 rats	34656
@NP	group	34667
@NP	the deep anesthesia by sodium pentobarbital -LRB- 40 mg/kg , i.p. -RRB-	34681
@NP	the deep anesthesia	34681
@NP	sodium pentobarbital -LRB- 40 mg/kg , i.p. -RRB-	34704
@NP	sodium pentobarbital	34704
@NP	40 mg/kg , i.p.	34726
@NP	40 mg/kg	34726
@NP	plasma	34743
@NP	the heart with EDTA	34769
@NP	the heart	34769
@NP	EDTA	34784
@NP	the anticoagulant when the rats were still in deep anesthesia	34792
@NP	the anticoagulant	34792
@NP	the rats	34815
@NP	deep anesthesia	34838
@NP	Rats	34855
@NP	0.9 % saline followed by 4 % paraformaldehyde	34899
@NP	0.9 % saline	34899
@NP	4 % paraformaldehyde	34923
@NP	The spinal cord segment from 1 cm caudal to 1 cm rostral of the injury epicenter	34944
@NP	The spinal cord segment	34944
@NP	1 cm caudal to 1 cm rostral of the injury epicenter	34973
@NP	1 cm caudal	34973
@NP	1 cm rostral of the injury epicenter	34988
@NP	1 cm rostral	34988
@NP	the injury epicenter	35004
@NP	the vertebral column and post-fixed in 4 % paraformaldehyde overnight	35044
@NP	the vertebral column	35044
@NP	post-fixed in 4 % paraformaldehyde overnight	35069
@NP	4 % paraformaldehyde	35083
@NP	4 ℃	35116
@NP	The tissues	35121
@NP	an ascending series of ethanol solutions	35157
@NP	an ascending series	35157
@NP	ethanol solutions	35180
@NP	xylene	35212
@NP	paraffin	35241
@NP	the paraffin blocks	35257
@NP	horizontal serial sections of 7 μm thickness	35291
@NP	horizontal serial sections	35291
@NP	7 μm thickness	35321
@NP	4.7	35337
@NP	ELISA The plasma samples	35342
@NP	ELISA	35342
@NP	The plasma samples	35348
@NP	3000g	35387
@NP	20 min at 4 ℃	35397
@NP	20 min	35397
@NP	4 ℃	35407
@NP	− 20 ℃	35430
@NP	ELISA	35437
@NP	the protocol	35467
@NP	rat BNDF ELISA kit -LRB- CUSABIO , Wuhan , China -RRB-	35483
@NP	rat BNDF ELISA kit	35483
@NP	CUSABIO	35503
@NP	Wuhan	35512
@NP	China	35519
@NP	the BDNF concentrations of OEC-M , Con-M and rats plasma samples	35537
@NP	the BDNF concentrations	35537
@NP	OEC-M , Con-M and rats plasma samples	35564
@NP	Values of BDNF	35602
@NP	Values	35602
@NP	BDNF	35612
@NP	the standard curve	35642
@NP	4.8	35662
@NP	Hematoxylin-eosin staining Sections	35667
@NP	dimethylbenzene	35719
@NP	decreasing concentrations of ethanol	35755
@NP	decreasing concentrations	35755
@NP	ethanol	35784
@NP	PBS	35807
@NP	hematoxylin	35830
@NP	5 min	35846
@NP	The tissue sections	35853
@NP	water followed by 1 % HCl in ethanol solution for 30 s.	35888
@NP	water	35888
@NP	1 % HCl in ethanol solution for 30 s.	35906
@NP	1 % HCl	35906
@NP	ethanol solution for 30 s.	35916
@NP	ethanol solution	35916
@NP	30 s.	35937
@NP	eosin for 6 min	35963
@NP	eosin	35963
@NP	6 min	35973
@NP	sections	35980
@NP	increasing concentrations of ethanol and dimethylbenzene	36013
@NP	increasing concentrations	36013
@NP	ethanol and dimethylbenzene	36042
@NP	4.9	36071
@NP	Immunohistochemistry Immunohistochemistry	36076
@NP	the expression of NF200	36142
@NP	the expression	36142
@NP	NF200	36160
@NP	Sections	36167
@NP	dimethylbenzene for 1 h	36191
@NP	dimethylbenzene	36191
@NP	1 h	36211
@NP	a descending ethanol solution series	36242
@NP	the rehydration by distilled water	36286
@NP	the rehydration	36286
@NP	distilled water	36305
@NP	endogenous peroxidase activity	36322
@NP	the incubation of 3 % hydrogen peroxide for 20 min	36368
@NP	the incubation	36368
@NP	3 % hydrogen peroxide for 20 min	36386
@NP	3 % hydrogen peroxide	36386
@NP	20 min	36411
@NP	Heatinduced epitope retrieval method	36419
@NP	the antigenic sites	36475
@NP	sections	36505
@NP	10 mmol/L sodium citrate buffer -LRB- pH 6.0 -RRB-	36529
@NP	10 mmol/L sodium citrate buffer	36529
@NP	pH 6.0	36562
@NP	a microwave oven	36577
@NP	98 ℃ for 20 min	36597
@NP	98 ℃	36597
@NP	20 min	36606
@NP	cold water for 10 min	36626
@NP	cold water	36626
@NP	10 min	36641
@NP	PBS	36668
@NP	Sections	36673
@NP	10 % goat serum albumin -LRB- Sigma -RRB-	36705
@NP	10 % goat serum albumin	36705
@NP	Sigma	36729
@NP	60 min at room temperature	36740
@NP	60 min	36740
@NP	room temperature	36750
@NP	the non-specific protein binding	36776
@NP	the 12 h incubation	36822
@NP	4 °C	36845
@NP	a mouse anti-rat NF200 monoclonal antibody	36855
@NP	a mouse anti-rat NF200	36855
@NP	2 μg/ml , Abcam , Cambridge , MA , USA	36899
@NP	2 μg/ml	36899
@NP	Abcam	36908
@NP	Cambridge	36915
@NP	MA	36926
@NP	USA	36930
@NP	a 15 min rinse in PBS	36942
@NP	a 15 min rinse	36942
@NP	PBS	36960
@NP	a rabbit anti-mouse biotin-labeled secondary antibody	36965
@NP	a rabbit	36965
@NP	anti-mouse biotin-labeled secondary antibody	36974
@NP	Beijing Biosynthesis	37020
@NP	sections	37061
@NP	HRP-conjugated streptavidin -LRB- Beijing Biosynthesis -RRB- for 30 min	37090
@NP	HRP-conjugated streptavidin -LRB- Beijing Biosynthesis -RRB-	37090
@NP	HRP-conjugated streptavidin	37090
@NP	Beijing Biosynthesis	37119
@NP	30 min	37145
@NP	25 ℃	37155
@NP	Diaminobenzidine -LRB- DAB -RRB- and hematoxylin	37161
@NP	Diaminobenzidine -LRB- DAB -RRB-	37161
@NP	Diaminobenzidine	37161
@NP	DAB	37179
@NP	hematoxylin	37188
@NP	reagent and counterstain	37213
@NP	The micrographs	37239
@NP	Image	37272
@NP	Pro Plus 6 -LRB- Media Cybernetics , USA -RRB-	37278
@NP	Pro	37278
@NP	6	37287
@NP	Media Cybernetics	37290
@NP	USA	37309
@NP	NF200-labeled area in the gray matter in each section	37315
@NP	NF200-labeled area	37315
@NP	the gray matter in each section	37337
@NP	the gray matter	37337
@NP	each section	37356
@NP	a threshold for background correction	37397
@NP	a threshold	37397
@NP	background correction	37413
@NP	NF200 positive density in the gray matter	37444
@NP	NF200 positive density	37444
@NP	the gray matter	37470
@NP	4.10	37502
@NP	Statistical analysis SPSS 23.0 -LRB- SPSS Inc , Chicago , IL , USA -RRB-	37508
@NP	Statistical analysis SPSS 23.0	37508
@NP	Statistical analysis	37508
@NP	SPSS 23.0	37529
@NP	SPSS Inc , Chicago , IL , USA	37540
@NP	SPSS Inc	37540
@NP	Chicago	37550
@NP	IL	37559
@NP	USA	37563
@NP	the statistical analyses	37581
@NP	Results	37607
@NP	the figures	37625
@NP	mean ± SD with n	37655
@NP	mean ± SD	37655
@NP	n	37670
@NP	the number of replicates	37685
@NP	the number	37685
@NP	LSD test	37711
@NP	the statistical significance between two groups	37741
@NP	the statistical significance	37741
@NP	two groups	37778
@NP	comparisons among multiple groups	37793
@NP	comparisons	37793
@NP	multiple groups	37811
@NP	two-way ANOVA of repeated measures	37848
@NP	two-way ANOVA	37848
@NP	repeated measures	37865
@NP	P	37884
@NP	0.05	37888
@NP	all the comparisons	37923
@VP	to treat contusive spinal cord injury -LRB- SCI -RRB-	284
@VP	treat contusive spinal cord injury -LRB- SCI -RRB-	287
@VP	was established by NYU weight-drop impactor at T10 segment	362
@VP	established by NYU weight-drop impactor at T10 segment	366
@VP	was performed to identify the purity of cultured OECs	584
@VP	performed to identify the purity of cultured OECs	588
@VP	to identify the purity of cultured OECs	598
@VP	identify the purity of cultured OECs	601
@VP	cultured OECs	624
@VP	was used to assess the functional recovery	649
@VP	used to assess the functional recovery	653
@VP	to assess the functional recovery	658
@VP	assess the functional recovery	661
@VP	were determined by ELISA	753
@VP	determined by ELISA	758
@VP	were applied to visualize the repair process of SCI	836
@VP	applied to visualize the repair process of SCI	841
@VP	to visualize the repair process of SCI	849
@VP	visualize the repair process of SCI	852
@VP	were carried out to evaluate the axonal regeneration	954
@VP	carried out to evaluate the axonal regeneration	959
@VP	to evaluate the axonal regeneration	971
@VP	evaluate the axonal regeneration	974
@VP	were significantly higher in OEC-M treated groups than in Con-M group	1106
@VP	demonstrated a better radiological recovery after SCI in OEC-M treated groups	1189
@VP	were accompanied with better outcomes	1292
@VP	accompanied with better outcomes	1297
@VP	promoted axonal regeneration around the injury epicenter	1383
@VP	was observed at the lesion site	1467
@VP	observed at the lesion site	1471
@VP	improves the functional recovery	1558
@VP	promotes the axonal regeneration around the injury epicenter after contusive SCI	1595
@VP	represents a novel cell-free OEC based therapy to effectively treat SCI	1691
@VP	based therapy to effectively treat SCI	1724
@VP	to effectively treat SCI	1738
@VP	effectively treat SCI	1741
@VP	1	1765
@VP	resulting in the permanent loss of motor , sensory and autonomic function	1838
@VP	is still a therapeutic challenge to date	2000
@VP	has been demonstrated to be beneficial -LRB- Tetzlaff et al. , 2011 -RRB-	2350
@VP	been demonstrated to be beneficial -LRB- Tetzlaff et al. , 2011 -RRB-	2354
@VP	demonstrated to be beneficial -LRB- Tetzlaff et al. , 2011 -RRB-	2359
@VP	to be beneficial -LRB- Tetzlaff et al. , 2011 -RRB-	2372
@VP	be beneficial -LRB- Tetzlaff et al. , 2011 -RRB-	2375
@VP	derived from the nerve fiber layer of olfactory bulb and nasal mucosa	2420
@VP	promoting property	2741
@VP	extensively studied as a promising candidate for the cell-based treatment of SCI	2776
@VP	facilitated neural regeneration	2946
@VP	induced locomotor function	2979
@VP	reduced progressive tissue loss	3007
@VP	are reported to be low	5194
@VP	reported to be low	5198
@VP	to be low	5207
@VP	be low	5210
@VP	indicates only a small number of transplanted OECs	5354
@VP	exert beneficial effects during a relatively short period post injury	5405
@VP	driving us to investigate a novel OECs based therapy for SCI	5575
@VP	to investigate a novel OECs based therapy for SCI	5586
@VP	investigate a novel OECs based therapy for SCI	5589
@VP	based therapy for SCI	5614
@VP	can promote neural regeneration	5733
@VP	promote neural regeneration	5737
@VP	needed for the cell transplantation	6029
@VP	facilitate functional recovery and axonal regeneration after a contusive SCI	6235
@VP	may provide a new cell-free OECs based therapy for spinal cord injury	6325
@VP	provide a new cell-free OECs based therapy for spinal cord injury	6329
@VP	based therapy for spinal cord injury	6358
@VP	2	6397
@VP	immunostained for	6470
@VP	merge image indicated > 90 % of cells were P75 +	6507
@VP	indicated > 90 % of cells were P75 +	6519
@VP	were P75	6544
@VP	is 50 μm	6565
@VP	results	6600
@VP	was evaluated every three days after the injury	6645
@VP	evaluated every three days after the injury	6649
@VP	is 6	6751
@VP	are represented as mean ± SD	6762
@VP	represented as mean ± SD	6766
@VP	was performed between two groups at each time point	6912
@VP	performed between two groups at each time point	6916
@VP	are described as mean ± SD	7366
@VP	described as mean ± SD	7370
@VP	were performed between two groups at a certain time point	7410
@VP	performed between two groups at a certain time point	7415
@VP	were compared between two time points in a certain group	7485
@VP	compared between two time points in a certain group	7490
@VP	scan	7778
@VP	are presented as mean ± SD	7915
@VP	presented as mean ± SD	7919
@VP	increased gradually after SCI	7953
@VP	was performed between two groups at each time point	8099
@VP	performed between two groups at each time point	8103
@VP	presented less noticeable changes after SCI	8366
@VP	indicates the injury site	8421
@VP	surrounded by a hperintense region at the contusive injury site	8586
@VP	indicates the injury site	8661
@VP	were stained dark purple	8916
@VP	stained dark purple	8921
@VP	was stained pink	8952
@VP	stained pink	8956
@VP	is 200 μm	8980
@VP	were stained brown	9090
@VP	stained brown	9095
@VP	were stained blue	9129
@VP	stained blue	9134
@VP	is 100 μm	9158
@VP	were stained brown	9287
@VP	stained brown	9292
@VP	were stained blue	9326
@VP	stained blue	9331
@VP	is 100 μm	9355
@VP	were calculated by Image Pro Plus 6	9593
@VP	calculated by Image Pro Plus 6	9598
@VP	are presented as mean ± SD	9635
@VP	presented as mean ± SD	9639
@VP	was compared between two groups at week 1 , week 3 and week 6 post surgery	9711
@VP	compared between two groups at week 1 , week 3 and week 6 post surgery	9715
@VP	was performed between two time points in each group	9801
@VP	performed between two time points in each group	9805
@VP	indicate that 93 ± 3.54 % of cells were P75NTR positive -LRB- Fig. 1 -RRB-	10392
@VP	were P75NTR positive -LRB- Fig. 1 -RRB-	10426
@VP	evaluated by BBB	10482
@VP	was used to evaluate the locomotor recovery after SCI	10530
@VP	used to evaluate the locomotor recovery after SCI	10534
@VP	to evaluate the locomotor recovery after SCI	10539
@VP	evaluate the locomotor recovery after SCI	10542
@VP	were no significant differences between groups	10892
@VP	comparing to the Con-M group , BBB scores of the low dose	10985
@VP	were significantly higher respectively -LRB- p < 0.05 -RRB-	11080
@VP	were determined by ELISA -LRB- BNDF ELISA kit , CUSABIO , Wuhan , China -RRB-	11436
@VP	determined by ELISA -LRB- BNDF ELISA kit , CUSABIO , Wuhan , China -RRB-	11441
@VP	were calculated based on the standard curve	11541
@VP	calculated based on the standard curve	11546
@VP	contained 183.64 ± 12.61 pg/ml and 39.12 ± 14.21 pg/ml BDNF respectively	11619
@VP	increased gradually -LRB- Fig. 3 -RRB-	11764
@VP	indicated that the OEC secretome were absorbed and distributed into the blood	11883
@VP	were absorbed and distributed into the blood	11916
@VP	absorbed and distributed into the blood	11921
@VP	affected the rat	11965
@VP	was slightly higher than low dose group -LRB- p > 0.05 -RRB-	12209
@VP	increased significantly from week 1 to week 3	12577
@VP	retained significant at week 6 -LRB- p < 0.05 -RRB- -LRB- Fig. 3B -RRB-	12643
@VP	were calculated at the lesion segment of spinal cord -LRB- Fig. 4 -RRB-	12975
@VP	calculated at the lesion segment of spinal cord -LRB- Fig. 4 -RRB-	12980
@VP	increased gradually	13048
@VP	were statistically significant at week 2 to week 6 -LRB- p < 0.05 -RRB-	13462
@VP	did n't present noticeable changes after the SCI -LRB- Fig. 5 -RRB-	13974
@VP	present noticeable changes after the SCI -LRB- Fig. 5 -RRB-	13981
@VP	Corresponding to the contusion site of the spinal cord	14125
@VP	was a region with decreased signal intensity surrounded by a hyperintense region	14187
@VP	surrounded by a hyperintense region	14232
@VP	depicted a shrinkage of the circumambient hyperintense regions	14379
@VP	extended in both rostral and caudal directions from the injury site	14641
@VP	demonstrated an increased signal intensity of the hyperintense region over time	14746
@VP	to visualize the repair process of spinal cord tracts -LRB- Fig. 7 -RRB-	14849
@VP	visualize the repair process of spinal cord tracts -LRB- Fig. 7 -RRB-	14852
@VP	tracks at different time points	14976
@VP	showed the disruption of nerve tracks	15056
@VP	was not obvious	15172
@VP	existed the irregularity of the nerve fiber	15225
@VP	appeared	15325
@VP	tracks retained at week 6 after surgery	15408
@VP	retained at week 6 after surgery	15415
@VP	comparing to the OEC-M	15481
@VP	was more severe in the Con-M group	15646
@VP	was found by the DTT images after the treatment	15754
@VP	found by the DTT images after the treatment	15758
@VP	revealed the morphologic changes of the lesion site -LRB- Fig. 8 -RRB-	15946
@VP	were confirmed by the HE staining in all three groups	16171
@VP	confirmed by the HE staining in all three groups	16176
@VP	staining in all three groups	16196
@VP	were not significant among three groups	16311
@VP	was more obvious at the injury site of OEC-M treated groups	16427
@VP	seen in the OEC-M treated groups , especially in the high dose OEC-M group	16567
@VP	was determined by immunohistochemistry	16761
@VP	determined by immunohistochemistry	16765
@VP	were applied as the primary and the secondary antibody respectively	16962
@VP	applied as the primary and the secondary antibody respectively	16967
@VP	were calculated -LRB- Fig. 11 -RRB-	17503
@VP	calculated -LRB- Fig. 11 -RRB-	17508
@VP	increased significantly at week 3 and week 6 post injury -LRB- p < 0.05 -RRB-	17630
@VP	3	17800
@VP	has been a promising candidate for the treatment of SCI	17865
@VP	been a promising candidate for the treatment of SCI	17869
@VP	secreted protein acidic rich in cysteine -LRB- SPARC -RRB-	18132
@VP	contains the secretome of OECs	18511
@VP	improved functional recovery	18625
@VP	promoted axonal regeneration around the injury epicenter	18658
@VP	was accompanied with the higher dose of OEC-M injection	18757
@VP	accompanied with the higher dose of OEC-M injection	18761
@VP	treated with OEC-M	18913
@VP	cultured OECs purified with the method of differential cell adhesion	19085
@VP	purified with the method of differential cell adhesion	19099
@VP	are significantly changed	19297
@VP	promote the neurite outgrowth and axonal regeneration	19358
@VP	become senescent	19579
@VP	lose their phenotypic properties progressively -LRB- Radtke et al. , 2010 -RRB-	19600
@VP	generated from postnatal day 2 rats	19721
@VP	purified by the differential cell adhesion method -LRB- Nash et al. , 2001 -RRB-	19758
@VP	cultured for totally 2 weeks	19832
@VP	was determined to be more than 90 %	19881
@VP	determined to be more than 90 %	19885
@VP	to be more than 90 %	19896
@VP	be more than 90 %	19899
@VP	were collected at passage 1	19951
@VP	collected at passage 1	19956
@VP	exhibits significant locomotor recovery after SCI -LRB- Guo et al. , 2016 -RRB-	20100
@VP	was confirmed by the BBB score	20264
@VP	confirmed by the BBB score	20268
@VP	hindered the plantar stepping	20784
@VP	stepping	20805
@VP	hampered the BBB score	20818
@VP	restricted in the area around the injury epicenter in all OEC-M treated groups	20937
@VP	thus may have limited the functional recovery to a certain extent	21020
@VP	have limited the functional recovery to a certain extent	21029
@VP	limited the functional recovery to a certain extent	21034
@VP	was absorbed and distributed into the blood of animals	21245
@VP	absorbed and distributed into the blood of animals	21249
@VP	increased in the OEC-M treated groups , especially in the high dose group	21415
@VP	contained 10 % fetal bovine serum -LRB- FBS -RRB-	21652
@VP	increased slightly	21723
@VP	contains 183.64 ±	21932
@VP	lasts up to 28 days -LRB- Popovich et al. , 1996 -RRB-	22251
@VP	are reported -LRB- Noble and Wrathall , 1989 ; Popovich et al. , 1996 -RRB-	22400
@VP	reported -LRB- Noble and Wrathall , 1989 ; Popovich et al. , 1996 -RRB-	22404
@VP	confirmed by the MRI and immunohistochemistry	22473
@VP	compromised even at day 56 after traumatic SCI -LRB- Cohen et al. , 2009 -RRB-	22537
@VP	to affect the injured spinal cord through the compromised BSCB	22763
@VP	affect the injured spinal cord through the compromised BSCB	22766
@VP	exerted their beneficial effects	22830
@VP	detecting the pathophysiology processes	23270
@VP	reflects the anisotropy of the diffusion	23487
@VP	is the most frequently used DTI parameter	23529
@VP	was accompanied with higher dose of OEC-M injection	23954
@VP	accompanied with higher dose of OEC-M injection	23958
@VP	enhance the nerve regeneration and preserve the axons at the injury segment	24075
@VP	enhance the nerve regeneration	24075
@VP	preserve the axons at the injury segment	24110
@VP	would facilitate the increase of FA values	24331
@VP	facilitate the increase of FA values	24337
@VP	was applied to visualize the repair process of the injured spinal cord	24392
@VP	applied to visualize the repair process of the injured spinal cord	24396
@VP	to visualize the repair process of the injured spinal cord	24404
@VP	visualize the repair process of the injured spinal cord	24407
@VP	did n't provide significant signal changes after SCI	24483
@VP	provide significant signal changes after SCI	24490
@VP	is known to detect edema and hemorrhage	24559
@VP	known to detect edema and hemorrhage	24562
@VP	to detect edema and hemorrhage	24568
@VP	detect edema and hemorrhage	24571
@VP	revealed obvious differences at different time points after the SCI	24600
@VP	indicated the hemorrhage within the spinal cord	24738
@VP	manifested as malacia	25036
@VP	extended in both rostral and caudal directions from the injury site	25208
@VP	reduced the malacia	25515
@VP	alleviated the secondary injury following the initial trauma of the spinal cord	25539
@VP	has been reported that DTT can identify the injury epicenter	25623
@VP	been reported that DTT can identify the injury epicenter	25627
@VP	reported that DTT can identify the injury epicenter	25632
@VP	can identify the injury epicenter	25650
@VP	identify the injury epicenter	25654
@VP	revealed the overall shape of the contusive injury epicenter	25993
@VP	was in accordance with our immunohistochemistry results	26269
@VP	were alleviated by the OEC-M treatment	26440
@VP	alleviated by the OEC-M treatment	26445
@VP	bridging	26689
@VP	exhibit migratory property -LRB- Lu et al. , 2006 ; Pearse et al. , 2007 -RRB-	27120
@VP	enhanced the beneficial effects of neurotrophic factors	27253
@VP	could promote the recovery of SCI	27410
@VP	promote the recovery of SCI	27416
@VP	staining	27474
@VP	revealed the pathological changes after the OEC-M treatment	27483
@VP	were more obvious than the Con-M group	27633
@VP	reacts broadly with axons and dendrites -LRB- Grady et al. , 1993 -RRB-	27720
@VP	promoted the axonal regeneration around the lesion epicenter	27817
@VP	showed that there was no obvious axonal regeneration across the injury epicenter	27903
@VP	was no obvious axonal regeneration across the injury epicenter	27921
@VP	formed by the astrocytes that eventually blocks the axonal penetration	28026
@VP	blocks the axonal penetration	28067
@VP	conditioned medium	28197
@VP	promoting the functional recovery and facilitating axonal regeneration	28258
@VP	promoting the functional recovery	28258
@VP	facilitating axonal regeneration	28296
@VP	based therapy	28355
@VP	circumvents the traditional limitations of OEC transplantation	28369
@VP	creates new possibilities for the future clinical applications in SCI	28436
@VP	researches	28512
@VP	achieve better axonal regeneration	28537
@VP	identify the specific factors responsible for these changes	28576
@VP	4	28638
@VP	established by the National Institutes of Health	28894
@VP	were divested with fine forceps under microscope and the olfactory nerve	29203
@VP	divested with fine forceps under microscope and the olfactory nerve	29208
@VP	dissected into small pieces	29303
@VP	adding 10 % fetal bovine serum -LRB- FBS , Gibco -RRB-	29460
@VP	was centrifuged at 1000 rpm for 5 min	29517
@VP	centrifuged at 1000 rpm for 5 min	29521
@VP	was discarded	29575
@VP	discarded	29579
@VP	were used to resuspend the cell pellet	29736
@VP	used to resuspend the cell pellet	29741
@VP	to resuspend the cell pellet	29746
@VP	resuspend the cell pellet	29749
@VP	described by Nash et al. -LRB- 2001 -RRB- to purify the primary OECs	29909
@VP	to purify the primary OECs	29941
@VP	purify the primary OECs	29944
@VP	coated with poly-L-lysine for immunofluorescence analysis	30066
@VP	being fixed in 4 % PFA for 20 min	30207
@VP	fixed in 4 % PFA for 20 min	30213
@VP	was used as the secondary antibody and the cells	30583
@VP	used as the secondary antibody and the cells	30587
@VP	were incubated for 60 min at room temperature	30632
@VP	incubated for 60 min at room temperature	30637
@VP	was added for 10 min at room temperature	30724
@VP	added for 10 min at room temperature	30728
@VP	were mounted in 50 % glycerol	30778
@VP	mounted in 50 % glycerol	30783
@VP	were photographed	30821
@VP	photographed	30826
@VP	were counted	30880
@VP	counted	30885
@VP	were trypsinized and subcultured in the culture medium described above	31006
@VP	trypsinized and subcultured in the culture medium described above	31011
@VP	described above	31061
@VP	was changed every two days	31089
@VP	changed every two days	31093
@VP	was collected at day 4 and day 6 after the subculturing	31141
@VP	collected at day 4 and day 6 after the subculturing	31145
@VP	were centrifuged at 2500 rpm for 10 min at 4 ℃	31217
@VP	centrifuged at 2500 rpm for 10 min at 4 ℃	31222
@VP	then filtered through a 0.4 μm filter to remove debris	31268
@VP	to remove debris	31306
@VP	remove debris	31309
@VP	mixed as the OEC conditioned medium -LRB- OEC-M -RRB-	31349
@VP	frozen at − 80 ℃ until used	31397
@VP	used	31419
@VP	was used as the control medium -LRB- Con-M -RRB-	31458
@VP	used as the control medium -LRB- Con-M -RRB-	31462
@VP	weighing between 250 and 300 g	31576
@VP	was then performed at T9-10 to expose the spinal cord	31843
@VP	then performed at T9-10 to expose the spinal cord	31847
@VP	to expose the spinal cord	31871
@VP	expose the spinal cord	31874
@VP	dropped from a height of 25.0 mm	32035
@VP	indicated the successful modeling of contusive spinal cord injury	32165
@VP	were sutured in separate layers	32266
@VP	sutured in separate layers	32271
@VP	was injected intramuscularly right after the surgery and then daily for 7 days	32320
@VP	injected intramuscularly right after the surgery and then daily for 7 days	32324
@VP	was administered post-surgery and daily by subcutaneous injection for 3 days	32430
@VP	administered post-surgery and daily by subcutaneous injection for 3 days	32434
@VP	were maintained with free access to food and water	32513
@VP	maintained with free access to food and water	32518
@VP	returned	32641
@VP	were sacrificed	32938
@VP	sacrificed	32943
@VP	were injected with 2 ml Con-M	32983
@VP	injected with 2 ml Con-M	32988
@VP	sacrificed	33343
@VP	were randomly chosen to do the diffusion tensor imaging	33417
@VP	chosen to do the diffusion tensor imaging	33431
@VP	to do the diffusion tensor imaging	33438
@VP	do the diffusion tensor imaging	33441
@VP	scan every week after the surgery	33479
@VP	were conducted at day 7 , 21 and 42 post surgery	33531
@VP	conducted at day 7 , 21 and 42 post surgery	33536
@VP	designed for scanning rats	33710
@VP	scan , which includes T1-weighted and T2-weighted images	33907
@VP	includes T1-weighted and T2-weighted images	33919
@VP	was applied to acquire the DTI images	34019
@VP	applied to acquire the DTI images	34023
@VP	to acquire the DTI images	34031
@VP	acquire the DTI images	34034
@VP	were in strict accordance with Li et al. -LRB- 2015 -RRB-	34125
@VP	scan	34184
@VP	to calculate the quantitative DTI parameter -LRB- FA value -RRB-	34328
@VP	calculate the quantitative DTI parameter -LRB- FA value -RRB-	34331
@VP	was reconstructed using the FuncTool software -LRB- GE Healthcare -RRB-	34439
@VP	reconstructed using the FuncTool software -LRB- GE Healthcare -RRB-	34443
@VP	using the FuncTool software -LRB- GE Healthcare -RRB-	34457
@VP	scan	34623
@VP	were still in deep anesthesia	34824
@VP	transcardially perfused with 0.9 % saline followed by 4 % paraformaldehyde	34870
@VP	followed by 4 % paraformaldehyde	34911
@VP	dehydrated through an ascending series of ethanol solutions	35138
@VP	cleared with xylene	35199
@VP	then embedded in paraffin	35224
@VP	were cut into horizontal serial sections of 7 μm thickness	35277
@VP	cut into horizontal serial sections of 7 μm thickness	35282
@VP	were centrifuged at 3000g for 20 min at 4 ℃ and then stored at − 20 ℃	35367
@VP	were centrifuged at 3000g for 20 min at 4 ℃	35367
@VP	centrifuged at 3000g for 20 min at 4 ℃	35372
@VP	then stored at − 20 ℃	35415
@VP	to measure the BDNF concentrations of OEC-M , Con-M and rats plasma samples	35526
@VP	measure the BDNF concentrations of OEC-M , Con-M and rats plasma samples	35529
@VP	were calculated based on the standard curve	35617
@VP	calculated based on the standard curve	35622
@VP	dewaxed in dimethylbenzene	35708
@VP	rehydrated through decreasing concentrations of ethanol	35736
@VP	washed in PBS	35797
@VP	then submerged in hematoxylin	35812
@VP	were washed in water followed by 1 % HCl in ethanol solution for 30 s.	35873
@VP	washed in water followed by 1 % HCl in ethanol solution for 30 s.	35878
@VP	followed by 1 % HCl in ethanol solution for 30 s.	35894
@VP	staining with eosin for 6 min	35949
@VP	were dehydrated through increasing concentrations of ethanol and dimethylbenzene	35989
@VP	dehydrated through increasing concentrations of ethanol and dimethylbenzene	35994
@VP	was performed to detect the expression of NF200	36118
@VP	performed to detect the expression of NF200	36122
@VP	to detect the expression of NF200	36132
@VP	detect the expression of NF200	36135
@VP	placed in dimethylbenzene for 1 h	36181
@VP	then deparaffinized in a descending ethanol solution series	36219
@VP	was blocked by the incubation of 3 % hydrogen peroxide for 20 min	36353
@VP	blocked by the incubation of 3 % hydrogen peroxide for 20 min	36357
@VP	was used to expose the antigenic sites	36456
@VP	used to expose the antigenic sites	36460
@VP	to expose the antigenic sites	36465
@VP	expose the antigenic sites	36468
@VP	cooled with cold water for 10 min	36614
@VP	then rinsed in PBS	36653
@VP	to block the non-specific protein binding	36767
@VP	block the non-specific protein binding	36770
@VP	was applied	37042
@VP	applied	37046
@VP	were used as reagent and counterstain	37200
@VP	used as reagent and counterstain	37205
@VP	were analysed by Image Pro Plus 6 -LRB- Media Cybernetics , USA -RRB-	37255
@VP	analysed by Image Pro Plus 6 -LRB- Media Cybernetics , USA -RRB-	37260
@VP	was measured after defining a threshold for background correction	37369
@VP	measured after defining a threshold for background correction	37373
@VP	defining a threshold for background correction	37388
@VP	was calculated	37486
@VP	calculated	37490
@VP	was used for the statistical analyses	37568
@VP	used for the statistical analyses	37572
@VP	were presented as mean ± SD with n representing the number of replicates	37637
@VP	presented as mean ± SD with n representing the number of replicates	37642
@VP	representing the number of replicates	37672
@VP	replicates	37699
@VP	was used to evaluate the statistical significance between two groups	37720
@VP	used to evaluate the statistical significance between two groups	37724
@VP	to evaluate the statistical significance between two groups	37729
@VP	evaluate the statistical significance between two groups	37732
@VP	were performed using two-way ANOVA of repeated measures	37827
@VP	performed using two-way ANOVA of repeated measures	37832
@VP	using two-way ANOVA of repeated measures	37842
@VP	was considered significant in all the comparisons	37893
@VP	considered significant in all the comparisons	37897
